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T-bet is a Type-1 transcription factor that regulates the development of Type-1 T cell and Type-1 
anti-tumor immunity. T-bet expression in Dendritic Cells (DC) is required for the ability of these 
antigen-presenting cells (APC) to prime Type-1-polarized T cell responses. Since T-bet is 
typically expressed by very low frequencies of activated DC (< 1%), we hypothesized that 
ectopic expression of T-bet as a consequence of recombinant adenovirus (rAd).T-bet transfection 
would yield a robust population of DC that were capable of (re)polarizing Type-1 anti-tumor T 
cell responses in vitro and in vivo. Indeed, human DC engineered to express high levels of T-bet 
strongly potentiated the development of Type-1 T cells from naïve T cells and concomitantly 
suppressed Th2 and Regulatory T cell (Treg) development in vitro. Interestingly, the superior 
Type-1 functionality of DC.Tbet seems to be largely independent of intrinsic Interleukin-12 (IL-
12) production, as IL-12 neutralizing antibody failed to affect the Type-1 T cell development 
driven by DC.Tbet. Furthermore, murine DC.Tbet displayed strong anti-tumor function when 
delivered into tumor sites as a cancer therapeutic modality.  The therapeutic efficacy of 
mDC.Tbet requires the participation of host NK cells and CD8
+
 T cells, whose induction was 
independent of the ability of injected mDC.Tbet to produce IL-12 family member cytokines or 
IFN-γ, or to migrate to tumor-draining lymph nodes (TDLN) based on CCR7 ligand chemokine 
recruitment. However, optimal therapeutic protection afforded by i.t. delivered mDC.Tbet did 
require that the injected DC express MHC class I molecules. Analysis of effectively treated 
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tumors revealed early recruitment/activation of NK cells and naïve T cells in the tumor 
microenvironment within 2 days of intratumoral delivery of DC.Tbet. Hence, my data support a 
model in which the injected mDC.Tbet serve as dominant drivers for the extranodal 
(cross)priming of therapeutic immunity within the tumor microenvironment (TME). 
Gene array analyses performed on human DC.Tbet and control DCs (DC.5) derived 
from 5 healthy donors revealed numerous differentially expressed genes between DC.Tbet and 
DC.5 that might associate with the Type-1 polarizing function of DC.Tbet.  
When taken together, my data suggest that DC.Tbet promote Type-1 anti-tumor 
immunity through multifaceted cellular and molecular mechanisms. 
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1.0  INTRODUCTION 
The immune system constantly monitors for and eliminates cancerous/precancerous cells through 
the process of immunosurveillance, at the same time, tumor cells also develop concerted 
mechanisms to promote immune tolerance and to escape immunosurveillance [1].  The goal of 
cancer immunotherapy is to break a state of immune tolerance to tumor cells, thereby promoting 
their eradication in vivo.  Successful anti-tumor immunity typically requires the generation of 
antigen-specific Type-1 CD8+ cytotoxic T cells (CTL/Tc1) that can directly kill cancerous cells, 
and CD4+ T helper 1 (Th1) cells that sustain CTL response(s) and memory CD8+ T cell 
expansion. The induction of anti-tumor T cell responses depends on the cross-presentation 
capability of dendritic cells which are the most potent antigen presenting cells (APCs) [2]. Ex 
vivo generated, antigen (Ag)-loaded DCs used in immunotherapies may enhance otherwise 
insufficient anti-tumor immunity in mice and humans. However, the limited success of DC-based 
cancer vaccines in the clinical setting suggests the necessity for further improvements in such 
therapies. 
T-bet (TBX21), a T-box transcription factor family member, is a key regulator of the 
Type-1 immunity. It plays a central role in the development and maintenance of effector function 
of Th1 cells and CTLs [3, 4]. Intrinsic T-bet expression in dendritic cells is directly associated 
with the T cell priming function of DCs and is important for the development of anti-tumor 
Type-1 immunity driven by DCs. Based on these notions, DCs engineered to express high level 
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of T-bet (DC.Tbet) would be presumed to possess improved Type-1 polarizing function, with an 
enhanced potential when used in cancer immunotherapy approaches. 
1.1 CANCER IMMUNOLOGY 
The theory that the immune system scans for and eliminates nascent transformed cells that 
continuously arise in our body was first proposed by Ehrlich in 1909. Later it was recognized 
that the interplay between the immune system and cancer not only restricts tumor growth, but 
that it might also ultimately facilitate tumor progression by modifying the antigenic nature of 
cancer cells and by activating counter-regulatory immune mechanisms that allow a cohort of 
tumor cells to escape immunologic control [1]. The term immunoediting has been used to 
describe this dual host-protective and tumor-promoting action of immunity. There are three 
phases involved in the immunoediting process: elimination, equilibrium and escape (the three 
“E” s) [5]. Advancement in the understanding of the immunoediting process should improve the 
efficacy of immunotherapeutic strategies. 
1.1.1 Immunosurveillance 
In the mid-20th century, Burnet and Thomas postulated that nascent cells could be recognized 
and eliminated by host immune system through the process of immunosurveillance [1, 6]. This 
theory was contentious until 1990s when experimental gene knock-out mouse models became 
available for evaluating the role of immune cellular components in monitoring and eliminating 
tumor growth. The critical role of host lymphocytes in limiting tumor growth was first proved in 
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the Rag2
-/- 
mouse model, in which Rag2
-/-
 mice defective in mature immune components T, B 
and NKT cells displayed an increased carcinogen-induced tumor incidence [2]. NK cells were 
also shown to restrict tumor growth, as depletion of these cells in C57BL/6 mice using either 
anti-NK1.1 (depletes both NK and NKT cells) or anti-asioGM1 (depletes NK cells and activated 
macrophages) antibodies rendered these mice 2-3 times more susceptible to spontaneous and 
chemically-induced tumor formation when compared to control wild-type mice [7, 8]. 
Accelerated tumor growth was observed in mouse models defective in mature immune effector 
mechanisms such as interferon-γ (IFN-γ) signaling (IFNγR-/-mice) and perforin (pfp-/- mice), 
suggesting important roles of these soluble immune factors in controlling tumor growth [9, 10]. 
Furthermore, the elevated incidence of non-oncoviral cancers in immunosuppressed transplant 
recipients when compared to the general population supported the important role of host 
immunity in tumor monitoring in human [11].  Such data suggest that immune system actively 
monitors and eliminates tumor development and progression via a range of effector cells and 
pro-inflammatory factors.   
1.1.2 Immune suppression and escape 
Immunosurveillance is not always successful as tumor develops counter-regulatory mechanisms 
to suppress protective immunity and evade immunosurveillance. First, the loss of surface antigen 
expression on tumor cells renders them invisible to CTLs. This occurs partially through the 
down-regulation of HLA class I expression, which is noted in many tumors including melanoma, 
colorectal carcinoma and breast carcinoma [12, 13]. The mechanism underlying the loss of HLA 
class I expression includes dysregulation in antigen processing and presentation machinery (i.e. 
β2-microglobulin and TAP1, TAP2) which have been reported in progressor tumors [14, 15]. 
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Second, defective death receptor signaling and lack of costimulation on tumor cells surface 
contribute to the survival of tumor cells. Two critical death receptors that control tumor 
development are Fas ligand and TRAIL. Fas ligand has cytoplasmic death domains which 
transmit apoptotic signals through caspase signaling, the expression of one caspase inhibitor 
(cFLIP) is believed to enhance the resistance to death receptor-mediated apoptosis in tumor cells 
[16]. Lack of costimulation molecules on tumor cell surface may also assist with tumor evasion 
as it could lead to T cell anergy and suboptimal activation of NK cells [17, 18]. Third, tumor 
cells produce immunosuppressive cytokines and chemokines to counter-regulate the function of 
immune effector cells and support the recruitment/development of immune suppressive cells 
such as Tregs and Myeloid Derived Suppressor Cells (MDSCs). Vascular endothelial growth 
factor (VEGF), for example, is over-expressed in many tumors and it supports tumor 
angiogenesis and mestastasis while suppresses DC maturation [19, 20]. Another inhibitory 
cytokine, IL-10, is also frequently increased in the serum of cancer patients, IL-10 suppresses the 
differentiation of DC from stem cell precursors and inhibits antigen presentation and the 
development of Type-1 T helper cell response in vivo [21, 22]. Similarly, high concentrations of 
TGF-β, Prostaglandin E2 (PGE2) are also found in cancer patients and are associated with 
disease progression  [23] [24].  
1.1.3 Cancer immunotherapy strategies 
Advancement in our understanding of tumor immunology facilitated the design of novel 
immunotherapies.  One promising strategy is the vaccine-based therapy that aimed at boosting 
host anti-tumor immune responses by enhancing the tumor associated antigen (TAA) 
presentation in tumor microenvironment (TME). Various modalities/adjuvants were explored in 
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this strategy, such as DC pulsed with TAA, DC fused to tumor cells, gene modified tumor cells 
and DNA based therapy using plasmid or viral vector. Systemic anti-tumor T cell responses 
including some complete responses were reported in several DC-based vaccine trials [25]. 
Another promising treatment strategy is the adoptive cell-based therapy, in which autologous 
lymphocytes were isolated from patients, expanded and modified ex vivo and then transferred 
back into patients to kill tumor cells. Recently, the chimeric antigen receptor (CAR) engineered 
T cell adoptive transfer strategy achieved great success in acute lymphoid leukemia (ALL) 
patients, with complete remissions observed in patients who had previously relapsed with 
aggressive B-cell malignancies [26]. Besides, recombinant cytokines and monoclonal antibodies 
were also used in cancer immunotherapy, with the intent to directly inhibit tumor growth and/or 
to indirectly restrict tumor growth through the action of these factors on angiogenesis and anti-
tumor immune function.  Many cytokines such as GM-CSF, IL-2, IL-7, IL-12, IL-15, IL-18, IL-
21 and IFN-α were explored for their potential to treat patients in clinical trials [27]. For 
instance, IL-2 has been firmly established as an effective treatment for advanced-stage 
melanoma/renal cell carcinoma [28], as is also the case for IFN-α in the treatment of chronic 
myeloid leukemia [29].  In addition, monoclonal antibodies have been designed to directly target 
tumor associated antigens/inhibitory costimulatory molecules in order to enhance anti-tumor 
immune responses [30]. For instance, the monoclonal antibody (BMS-936558) which blocks 
inhibitory PD-1 signaling (thereby enhancing anti-tumor T effector cell survival) and 
trastuzumab which binds to extracellular domain of HER2 and inhibits the survival of HER2-
dependent breast cancer cells have each yielded objective responses in a fraction of treated 
patients [31, 32]. 
 6 
1.2 DENDRITIC CELLS AS CANCER IMMUNOTHERAPEUTIC AGENTS 
DCs are the most potent antigen presenting cells that play a key role in the initiation and 
modulation of immune responses [33]. Upon encountering foreign antigens or antigens released 
from tissue damages, DCs capture and process Ags into peptides that could bind to MHC class I 
or MHC class II molecules, and subsequently migrate to the lymphoid organs, where they 
present MHC-peptide molecules to CD8
+ 
or CD4
+
 T-helper cells. Ag-loaded DCs provide 3 
signals to T cells via: 1) engagement of MHC-peptide complex with appropriate TCR; 2) 
interaction of costimulatory and accessory molecules that stabilize peptide MHC/TCR 
interactions at the immune synapse and sustain enhanced T cell proliferation and maturation; and 
3) secretion of the polarizing cytokines which determine the differentiation direction of the T cell 
(Type-1, Type-2, Th3 or Th17, Treg) [34, 35]. In the cancer setting, DCs orchestrate innate and 
adaptive anti-tumor immune responses. DCs promote tumor cell apoptosis through enhancement 
of cytotoxic functions mediated by NK cells, NKT cells and DCs [36, 37]. Locoregionally-
released tumor-associated Ags may be captured by DCs and (cross) presented to TAA-specific T 
cells [38]. Effective homing of TAA-specific T cells into the tumor site and cognate recognition 
of tumor cells by specific effector cells may lead to the elimination of tumor cells in vivo [39]. It 
is important to keep in mind that DCs exhibit considerable plasticity in their ability to skew Th 
responses in the tumor microenvironment.  For example, DCs that normally inducing Th1 
profiles can be subverted to Th2-skewing DCs when treated with anti-inflammatory cytokines 
such as IL-10 and TGF-β or with PGE2 [21, 40], which are commonly found in abundance in the 
TME. Hence, host DC may be subverted by the TME to be ineffective promoters of protective 
immunity. 
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The unique ability of DCs to induce and sustain primary immune responses makes them 
prime candidates for vaccination protocols in the cancer setting [41]. DC-based cancer vaccines 
are one of the most attractive anti-tumor immunotherapies that aim to induce both therapeutic 
and protective T cell immunity (tumor specific memory T cells that can control tumor relapse) in 
cancer patients. The efficacy of DC-based cancer vaccine depends on numerous DC- or host-
related factors, including subsets, the maturation and activation status, and migratory potential of 
applied DCs, Ag dose loaded onto DC, vaccination schedule, route of injection and the disease 
stage of the patients, among others [36, 41]. DCs capable of eliciting effective anti-tumor Type-1 
immunity are considered as desirable candidates for cancer vaccination [42]. Clinical trials using 
DC-based cancer vaccine have now been conducted in a broad range of cancer types, including 
melanoma, lymphoma, myeloma, prostate and renal cell cancer [41]. All published trials have 
demonstrated the safety of such approaches. In clinical trials using monocyte-derived, peptide-
pulsed DCs fully-matured under rigorous quality control parameters (GM-CSF/IL-4 followed by 
IL-1β, TNF-α, PGE2, IL-6), two groups have reported clinical and immunological responses in 
melanoma or renal cancer patients , especially in those patients with a low tumor burden [43, 
44]. Overall, tumor regression has only occurred in a very minor subpopulation of treated 
patients, suggesting the necessity to further optimize DC-based therapies in order to maximize 
the prophylactic or therapeutic anti-tumor immunity.  
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1.3 T-BET AND ITS MULTIFACETED ROLE IN PROTECTIVE TYPE-1 
IMMUNITY 
T-bet (T-box expressed in T cells, Tbx21) is a T-box family transcription factor that regulates 
Type-1 immunity [45]. It controls T helper 1(Th1) lineage commitment, and the development 
and/or maintenance of effector cell fates in T, B, DCs and NK cells [46]. T-bet controls the 
production of IFN-γ and regulates the expression of chemokines and chemokine receptors which 
controls the recruitment/trafficking of Th1 cells. 
1.3.1 T-bet in T lymphocytes 
T-bet was first identified by the Glimcher group as a Th1-specific transcription factor [45]. It 
controls IFN-γ, IL12Rβ and CXCR3 expression in Th1 cells and directs Th1 commitment [47-
49]. Retroviral transduction of T-bet into polarized Th2 or Tc2 (CD8 T cells that producing IL-4) 
cells redirected these cells to become Th1/Tc1 cells by inducing IFN-γ production while 
repressing IL-4, IL-5 production in these cells [45]. Mice lacking T-bet (T-bet
-/-
) failed to 
develop Th1 cells and displayed a dramatic reduction of IFN-γ production by CD4+ T cells and 
NK cells, with an increase in Th2 responses in vivo in association with airway hyperactivity [4]. 
Such data support the dominant and non-redundant role of T-bet in the development/commitment 
of Th1-polarized T cells.  
 In CD8 T cells, T-bet plays a important role in the development and function of the 
effector CD8
+
 T cell (CTL) by controlling the production of IFN-γ, perforin and granzyme of 
CTLs [50-52]. However in contrast to its role in CD4
+
 T cells, T-bet, together with another T-
box transcription factor Eomes, function in a cooperative and partially redundant way to regulate 
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effector gene expression in CD8
+
 T cells. It is reported in several studies that a substantial 
portion of CD8
+ 
T effector function was preserved in the absence of T-bet [52-54], while mice 
with compound mutations in the gene encoding Eomes and T-bet displayed additive defects in 
effector gene expression by CD8
+
 T cells and NK cells. Further studies suggested that T-bet and 
Eomes were closely associated with the expression of CD122 (the receptor specifying IL-15 
responsiveness) which was required to drive proliferative renewal of memory CD8
+
 T cells in the 
absence of pathogen stimulation/attack [55-58]. Therefore, in CD8
+
 T cells T-bet collaborate 
with Eomes to control the effector CTL responses and long-term renewal of memory CD8
+
 T 
cells to their effector potency. 
1.3.2 T-bet in dendritic cells 
T-bet is expressed in human and mouse DCs. In human DCs, T-bet can be induced through an 
ERK-dependent pathway [59]. In unstimulated, murine splenic DCs, T-bet is expressed at low 
constitutive levels. However, upon stimulation with IFN-γ, T-bet expression is rapidly elevated 
(and comparable to level found in Th1 cells [4]). T-bet is required for IFN-γ production from 
DCs, but is not essential for the development or migration of DCs. T-bet also regulates the T cell 
priming/polarizing function of DCs, as T-bet
-/-
 dendritic cells fail to activate Th1 programming 
in adoptively transferred antigen-specific T cells [4]. Wang et al. reported the essential role of T-
bet in inflammatory arthritis (CAIA model in mice), and T-bet
-/-
 mice were largely resistant to 
the development of inflammatory arthritis [60]. They also observed that T-bet
-/-
 DCs were 
defective in activating T cells, as adoptively transfer of KLH-pulsed T-bet
-/-
 DCs failed to prime 
Ag-specific T cells in vivo. In the same study, T-bet was found to control the production of 
several proinflammatory cytokines and chemokines by DC (such as IL-1α, macrophage 
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inflammatory protein-1α (MIP-1α) and thymus- and activation-related chemokine (TARC)) after 
stimulation with LPS [60]. These studies support an important role for T-bet in DCs, by linking 
both innate and adaptive immunity in order to effectively promote Type-1 immunity in vivo.  
1.3.3 T-bet in other immune cells 
T-bet has been implicated in controlling the maturation and effector function of NK cells. T-bet
-/-
 
NK cells do not fully mature and are sensitive to apoptosis.  T-bet deficiency also results in 
reduced NK cell numbers and diminished egress of NK cells from the bone marrow and lymph 
nodes into the blood circulation [61]. As in the case of CD8
+
 T cells, T-bet acts together with 
Eomes in a spatial-temporal manner to control NK cell development, with T-bet stabilizing the 
immature TRAIL
+
 NK pool, and Eomes supporting the maturation of TRAIL
+
 NK cells into 
mature DX5
+
 NK cells while T-bet and Eomes are both required for the later stages of NK 
maturation into DX5
+
CD11b
+
 NK cells [61]. With regard to NK effector function, T-bet controls 
Granzyme B production in NK cells, while Eomes upregulates IFN-γ and Granzyme C 
expression in NK cells. T-bet expression in NK cells is associated with the enhanced ability of 
these effector cells to inhibit cancer metastasis (due at least in part to the enhanced longevity and 
functionality of NK cells), and T-bet
-/-
 mice are susceptible to melanoma development, 
potentially due to impaired NK-driven innate immune responses which serve as a prelude to the 
development of an effective adaptive anti-tumor immune response [62]. In B cells, T-bet appears 
to be required to control Type-1-polarized effector cell fate [63].  These data suggest that T-bet 
exerts functional immunomodulatory pressure within a broad range of immune cell lineages.  
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1.4 TYPE-1 IMMUNITY AND TYPE-1 T CELL DEVELOPMENT 
1.4.1 The critical role of Type-1 immunity in cancer immunology 
Type-1 innate and adaptive immunity are the major components of host anti-tumor protective 
responses. The main effector cells shown to mediate anti-tumor function are Type-1 CD8
+
 cells 
(CTLs) and CD4
+
 helper (Th1) cells. Tc1 cells are IFN-γ secreting CD8+ T cells that directly kill 
tumor cells [33, 64]. Development of Tc1 cells requires assistance from Th1 cells, which activate 
(i.e. licensing) APC and enhance the expression of both MHC and costimulatory molecules on 
APC to cross-prime CD8
+
 T cell responses. Th1 also may directly activate CTLs by secreting 
IFN-and IL-2 to support CTL function and the secondary expansion of memory CD8+ T cells 
[Ref]. Type-1 DC produce high levels of IL-12p70 and efficiently promotes Th1 and Tc1 
development from naïve T cells, hence the therapeutic upreulation of IL-12 production by DC in 
vivo represents a preferred clinical endpoint of many cancer immunotherapies [42, 65-68]. 
Besides the adaptive Type-1 immune effectors, Type-1 macrophages (M1) have also been shown 
to be proinflammatory in nature, allowing for the enhanced priming of Type-1 anti-tumor T cell 
responses [69]. In conclusion, both Type-1 innate and adaptive immunity play critical roles in 
preventing and eliminating tumors in vivo. 
1.4.2 Type-1 T cell development 
The differentiation of naïve CD4 T cells starts when TCR encounters MHC II-peptide complex 
presented on an APC. Upon TCR engagement, 3 major signals direct T helper (Th) 
differentiation: the TCR signal (strength and duration), signals from ligation of co-stimulatory 
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molecules and from local cytokine environment [70]. Among these signals, the cytokine milieu 
is considered as the most potent factor that determines Th cell fate, with IL-12p70 inducing Th1 
lineage commitment and IL-4 directing Th2 lineage development. Th1 lineage is characterized 
by the production of proinflammatory cytokine IFN-γ and is known to control intracellular 
infection or tumor growth; while Th2 lineage produce cytokines IL-4, IL-5 and IL-23, and 
eliminates parasitic infections [71], [72].  
T-bet expression in Th1 cells is induced by TCR signaling and strongly elevated by the 
IFN-γR/STAT1 signal transduction pathways [73, 74]. T-bet transactivates IFN-γ gene 
transcription, upregulates the expression of IL-12Rβ on newly-activated T cells and stabilizes its 
own expression through the autocrine effect of IFN-γ in an autocatalytic loop [47],[75]. 
Concomitantly, T-bet suppresses Th2 cell commitment by repressing the expression of IL-4 and 
GATA-3 which controls Th2 cell fate [76, 77]. Other transcription factors that are involved in 
Th1 development include: Runx3 which together with T-bet binds to enhancers and the 
promoters of IFN-γ gene thereby promoting IFN-γ expression; Hlx, a Th1-specific homeobox 
gene that appears to interact with T-bet to enhance the transcription of a group of T-bet regulated 
genes [77]; also T-bet interacts with Bcl-6 to repress genes that are critical in opposing Th cell 
fates [78, 79]. Hence, T-bet cooperates with other transcription factors to fortify Th1 cell fate.  
Historically, IL-12 has been considered the most potent Th1 initiating cytokine, and one 
that is indispensable for Th1 development, however, more recent studies suggest that IL-12 is not 
essential at least under certain stage/circumstances of Th1 differentiation, and there are other 
cytokines such as IFN-γ, IL-23, IL-27, IL-18 that may promote Th1 differentiation.  As 
described by Schulz et al., there are at least two sequential phases of T-bet expression and 
activation of IFN-γ gene transcription during Th1 development [80]. In the first phase, TCR 
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signaling collaborates with IFN-γ signaling to induce T-bet expression while TCR signaling 
restricts IL-12Rβ expression on the T cell surface; in the second phase, diminished TCR 
engagement derepresses IL-12Rβ which increases the responsiveness of T cells to IL-12. IL-12 
at this stage is the principle driver for T-bet expression and reinforces Th1 commitment. These 
data suggest that IL-12 is dispensable at least in initiation phase of Th1 development and it 
serves more to stabilize the Th1 cell fate than initiating Th1 differentiation.  
Th1 lineage commitment is also controlled by epigenetic mechanisms. For example, T-
bet recruits chromatin remodeling complexes including Jmjd3 (H3K27-demethylase) to target 
the removal of the repressive H3K27me3 modification in order to activate Th1 signature genes 
[81]. These complexes help to establish a more permissive chromatin state which retains the 
capacity of opposing Th lineages to re-express T-bet target genes. The epigenetic regulation of 
Th1 gene expression leads to the flexibility of Th cells that are amenable to repolarization signals 
as opposed to terminally polarized T cell subsets [80, 82, 83]. 
1.5 THE DEVELOPMENT AND FUNCTION OF TERTIARY LYMPHOID ORGAN 
In the classical model of peripheral T cell activation, tissue resident DCs capture antigens (such 
as foreign pathogens, tumor cell debris, etc.) in an inflammatory microenvironment, leading to 
the migration of antigen-laden CCR7
+
 DCs to regional draining lymph nodes [LN; aka secondary 
lymphoid organs (SLO)], where activation of cognate T cells occurs [84, 85]. After appropriate 
proliferative expansion and maturation, T effector cells may then enter the blood circulation and 
be recruited into tissue sites where they are competent to recognize and react against relevant 
APCs, such as virally infected host cells or tumor cells [86]. Recent evidence obtained in a range 
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of translational and clinical models suggests, however, that this classical/conventional paradigm 
may be operationally overly simplistic, and that extranodal (cross)priming of antigen-specific T 
cells can occur in peripheral tissues, often times in conditionally established tertiary lymphoid 
organs (TLO)  [87-89]. 
 
1.5.1 The Role of Tertiary Lymphoid Organ (TLO) in diseases 
While classical SLO are encapsulated structures that develop in predictable locations as a 
consequence of normal immune system development, under pathologic conditions, ectopic 
lymphoid tissues (aka TLO) may develop in peripheral tissue sites of chronic inflammation. 
Similar to SLO, TLOs have typical lymphoid features including segregated B cell follicals and T 
cell enriched areas, HEV, germinal center and follicular DCs [90]. TLOs in inflammation sites 
are believed to promote immune responses against self-protein (autoimmune diseases) or 
neoantigens (cancer) through concentrating antigens and lymphocytes, and thus increasing the 
efficiency of interactions between antigen-specific lymphocytes and antigen presenting cells 
locally in the inflammation site. TLO formation has been reported within inflamed organs of 
patients with rheumatoid arthritis [91], psoriatic arthritis [92], autoimmune gastritis [AIG; Ref. 
[93]], juvenile dermatomyositis [94], and Sjögren’s syndrome [95], among others. TLO 
formation has also been identified in the lungs of influenza virus-infected mice [96], the livers of 
hepatitis C virus (HCV)-infected patients [97] and in the stomachs of patients infected with 
Helicobacter pylori [98]. “Dysfunctional” human lung allografts exhibiting chronic 
inflammatory responses have also been found to commonly contain TLO [99].  
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 Furthermore, a burgeoning literature supports tumor associated TLO as important sites 
of extranodal T cell priming and epitope spreading in the responder T cell repertoire [90, 100]. 
TLO have been identified in a subset of human melanoma lesions, in which mature DC were 
found to maintain intimate contact with recruited T cell populations, consistent with the notion of 
operational extranodal (cross)priming within the tumor microenvironment (TME) [101, 102]. 
Similar results have been reported for murine melanoma models [88, 103]. In line with this 
model, naïve lymphocytes have been identified in TLO within pulmonary lesions of patients with 
lung cancer, making it likely that these immune cells encountered their cognate antigen for the 
first time and developed into antigen-specific T effector cells within the TME in vivo [104, 105]. 
TLO featuring DC/Type-1 T cell clusters proximal to B cell “nests” have been identified in 
human non-small cell lung cancer specimens [106]. In such instances, the density of mature DC 
found in TLO appeared to be associated with improved long term survival [106, 107].  
Furthermore, Mulé and colleagues have recently performed a metagene analysis on human 
(Stage IV, non-locoregional) melanoma metastases and identified a 12-chemokine gene signature 
(i.e., CCL2, CCL3, CCL4, CCL5, CCL8, CCL18, CCL19, CCL21, CXCL9, CXCL10, CXCL11, 
CXCL13) correlating with the presence of TLO (containing CD20
+
 B cell follicles with 
prominent areas of CD4
+
and CD8
+
 T cells, but not FoxP3
+
 Treg cells), with better overall 
survival noted in the TLO
+
 subset of patients [101].  
1.5.2 The developmental formation of SLO and TLO 
The developmental formation of SLO is believed to require the interaction of so-called lymphoid 
tissue inducer cells [14] bearing a CD3-CD4+CD45+IL-7R+c-Kit+ phenotype that produce 
lymphotoxin α/β [LT α/β; Ref. [108, 109]] with LTβR+ stromal “organizer” cell populations that 
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may derive from adipocyte precursors [110], leading to corollary stromal cell elaboration of the 
SLO homeostatic chemokines CCL19, CCL21, and CXCL13 [87, 90, 103, 111, 112]. These 
chemokines sustain recruitment of LTi and other lymphocytes into SLO, resulting in the 
development of a mature lymphoid organ architecture [i.e., based on the formation of follicular 
structures containing B cells and surrounding “cortical” zones that are diffusely populated by 
CD4
+
 and CD8
+
 T cells,  antigen-presenting cells (including CD11c+ DC), and PNAd
+
 high-
endothelial venules (HEV]  [99, 103, 105] . 
 The conditional formation of TLO in peripheral tissues appears to require the 
collaboration of a similar cast of cellular participants, soluble mediators, and signaling pathways 
associated with the orchestration of SLO development [111, 112].  Ectopic delivery of LTα/β or 
LIGHT (aka TNFSF-14 or CD258) promotes PNAd
+
 HEV, CCL19/CCL21 production, massive 
naïve T cell infiltration, and (tumor-specific) cross-priming in the context of TLO structures [87, 
96, 109, 113-115]. Consistent with these findings noted for pro-TLO immunobiology of LTβR 
ligands, blockade of the LTβR precludes formation of TLO in vivo [116]. Unlike SLO 
organogenesis, the induction of TLOs doesn’t seem to require LTi [117]; instead, the interaction 
between mature CD3
+
CD4
+
 T cells and dendritic cells are believed to trigger the development of 
TLOs [118], [119].  
1.5.3 Therapeutic Promotion of TLO 
The potential role of TLOs in increasing local anti-tumor immune responses prompted 
immunotherapy strategies aimed at enhancing TLO development in TME to improve the clinical 
outcome. Perhaps the most strategically simple means to apply this paradigm in the cancer 
setting reflects the implantation of SLO/TLO directly into the TME. Recently, scaffold-based 
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lymphoid tissue engineering has been developed as a means to transplant “intact” TLO directly 
into tumors in order to affect clinical benefit [120]. A previously mentioned alternative to this 
strategy is clearly the delivery of the LTβR ligands (LTα, LTβ, or LIGHT), agonist anti-LTβR 
antibodies or downstream TLO-associated chemokines (CCL19, CCL21, CXCL13) via protein-
based or genetic therapy in order to instigate the locoregional development of TLO in the TME 
leading to inhibition of tumor growth in vivo and extended overall survival [87, 103, 114, 121, 
122].  
It also appears that the administration of appropriately activated/engineered DC is 
sufficient to nucleate and/or maintain the development of TLO in vivo [97, 123]. For instance, 
mice vaccinated sub-cutaneously with syngenic DC loaded with apoptotic/necrotic B16 
melanoma cell debris developed operational TLO [pseudocapsule; PNAd
+
 vascular endothelial 
cells (VEC), T cell/DC infiltrates] at sites of injection, leading to the activation of protective 
anti-tumor immunity [123]. DC genetically engineered to secrete high-levels of CCL21 
(DC.CCL21) and injected directly into B16 murine melanomas promoted strong extranodal T 
cell crosspriming/recruitment into the TME, even in LTα-/- mice that lack SLO [103, 123, 124]. 
The superiority of DC.CCL21 in enhancing the cross-priming of protective Type-1 anti-tumor T 
cell responses has also been confirmed in alternate murine models [125]. 
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1.6      STATEMENT OF THE PROBLEM  
DC-based cancer immunotherapies have been shown to be safe and capable of inducing Ag-
specific immune responses in clinical trials, however, the overall clinical benefits were still 
statistically insignificant [126, 127]. This is partly due to the suppressive TME that restricts DC-
mediated functions (including the ability to prime antigen-specific T cells and to produce pro-
inflammatory cytokines/chemokines), leading to adaptive immune polarization towards non-
protective Type-2 or regulatory responses [128-130]. T-bet is a Type-1 immune cell-associated 
transcription factor that is required for the development in anti-tumor immunity at the level of 
NK cells, DC and T cells [131].   One aim in my study was to generate a strongly Type-1 
polarized population of DC through highly expressing T-bet and would be capable of promoting 
robust Type-1 T cell priming from naïve responder cell populations (including CD8
+
 CTLs), 
while coordinately suppressing Type-2 and Treg responses in vitro. When translated to tumor-
bearing mice, these gene-modified DC would be envisioned to serve as a cellular therapy 
designed to overcome existing immune suppression in the TME, thereby allowing for renewed 
promotion of effective anti-tumor immune responses in vivo.   
Animal models are important tools for the investigation of the therapeutic benefits of 
cancer immunotherapies prior to their assessment in randomized clinical trials, as these models 
allow for the in-depth study of locoregional and systemic immune responses/mechanisms 
relevant to effective treatment (i.e. in the TME, TDLN and Spleen).  In my study, C57BL/6 mice 
bearing established s.c. MCA205 sarcomas were used to evaluate the therapeutic efficacy of 
DC.Tbet-based therapy, with the possibility of subsequently resolving the underlying 
mechanism(s) of action using an extensive panel of syngenic gene knock-out mice. 
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IL-12 is an important pro-inflammatory cytokine that promotes anti-tumor immunity by 
enhancing Type-1 T cell function, promoting effector CTL differentiation and inhibiting 
angiogenesis [132]. Many DC-based cancer vaccines have been based on the engineering of DC 
to produce high levels of IL-12p70 in hopes of augmenting the Type-1 cross-priming function of 
these APCs [133, 134]. Interestingly, I observed that DC.Tbet promoted Type-1 T cell 
development and anti-tumor Type-1 immunity independent of their intrinsic capacity to produce 
IL-12p70, suggesting that DC.Tbet utilize a novel anti-tumor mechanism that is distinct from 
what known to be employed by conventional DC.  Understanding this unique mechanism will be 
necessary for the rational design and improvement of DC.Tbet-based (combinational) therapies 
for use in prospective human clinical trials targeting cancer management and eradication. Based 
on gene array analyses and transgenic mouse models, I was able to identify molecular and 
cellular components associated with the potent Type-1 polarizing function and anti-tumor 
benefits linked to DC.Tbet. 
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2.0  ECTOPIC T-BET EXPRESSION LICENSES DENDRITIC CELLS FOR 
INTERLEUKIN-12 INDEPENDENT PRIMING OF TYPE-1 T CELLS IN VITRO 
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2.1 ABSTRACT 
T-bet (TBX21) is a transcription factor required for the optimal development of Type-1 immune 
responses. Although initially characterized for its intrinsic role in T cell functional polarization, 
endogenous T-bet may also be critical to the licensing of Type-1-biasing APCs. Here, we 
investigated whether human dendritic cells (DC) genetically engineered to express high levels of 
T-bet (i.e., DC.Tbet) promote superior Type-1 T cell responses in vitro. We observed that 
DC.Tbet were selective activators of Type-1 effector T cells developed from the naive pool of 
responder cells, whereas DC.Tbet and control DC promoted Type-1 responses equitably from the 
memory pool of responder cells. Naive T cells primed by (staphylococcal enterotoxin B or 
tumor-associated protein-loaded) DC.Tbet exhibited an enhancement in Type-1- and a 
concomitant reduction in Th2- and regulatory T cell-associated phenotype/function. Surprisingly, 
DC.Tbets were impaired in their production of IL-12 family member cytokines (IL-12p70, IL-
23, and IL-27) when compared with control DC, and the capacity of DC.Tbet to preferentially 
prime Type-1 T cell responses was only minimally inhibited by cytokine (IL-12p70, IL-23, IFN-
γ) neutralization or receptor (IL-12Rβ2, IL-27R) blockade during T cell priming. The results of 
transwell assays suggested the DC.Tbet-mediated effects are predominantly the result of direct 
DC-T cell contact or their close proximity, thereby implicating a novel, IL-12-independent 
mechanism by which DC.Tbets promote improved Type-1 functional polarization from naive T 
cell responders. Given their superior Type-1 polarizing capacity, DC.Tbet may be suitable for 
use in vaccines designed to prevent/treat cancer or infectious disease.  
. 
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2.2 INTRODUCTION 
Dendritic cells (DC) are professional APCs that capture, process, and present Ags to T cells in 
the form of peptides complexed with MHC molecules. heath [ref] DCs support the activation and 
functional maturation of Th1, Th2, Th17, and regulatory CD4
+
 T cells, as well as CD8
+
 T cells, 
NK cells, and innate myeloid immune cells [135-137]. 
In a diverse array of infectious disease states and in the cancer setting, host protection is 
largely afforded via the generation of Type-1 immunity. Type-1 T cell induction is believed to 
require DC presentation of cognate Ag, in addition to costimulator molecules, such as B7 and 
TNF family member molecules, and polarizing cytokines, such as IL-12, IL-23, and IL-27 [138, 
139]. Functional polarization of Type-1 T cells can be augmented by IL-12 and IL-27, which act 
through STAT4 and STAT1, respectively, to promote IFN-γ and Type-1-associated accessory 
molecules [140, 141]. However, IL-12/STAT-4-independent mechanisms of Type-1 T cell 
induction have also been reported [142, 143]. In such cases, Type-1 polarization requires 
intrinsic expression of the T-bet transcription factor in T cells which is regulated in a TCR- and 
STAT1-dependent manner [144-146]. Silencing of T-bet in T cells suppresses IFN-γ and STAT1 
expression levels during Ag-specific T cell differentiation, resulting in the unbalanced 
development of IL-4-secreting Th2 cells [147, 148]. Conversely, T-bet expression suppresses 
Th2 differentiation by interfering with the type 2 trans activator GATA-3 [149, 150].  
Intrinsic, low-level expression of T-bet in (at least a subset of) DC also appears crucial to 
the generation of Type-1 immunity [144, 151-153]. Our results suggest that human DCs, 
engineered using recombinant adenovirus to express high levels of T-bet protein in a high 
percentage of DC, selectively prime and expand Type-1 T cells from naive precursors in vitro, 
while concomitantly restricting Th2 and regulatory T cell (Treg) polarization profiles. Human 
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DCs genetically engineered to express high levels of T-bet (i.e., DC.Tbet) pulsed with tumor Ag-
derived protein or peptide epitopes proved to be superior activators of melanoma Ag-specific 
Th1 and Tc1 effector cells in vitro, thereby supporting the potential utility of these APCs in 
vaccines against infectious disease or cancer.  
2.3 MATERIALS AND METHODS 
Preparation of DC and T cells. DCs (>98% CD11c
+
CD14
−
) were generated from normal donors 
with written consent under an Institutional Review Board-approved protocol, as previously 
described [65]. Where indicated, day 5 immature DCs were activated for 24 h by incubation with 
inflammatory stimuli including 1) IL-1β (25 ng/ml; Sigma-Aldrich) plus TNF-α (50 ng/ml; 
Sigma-Aldrich) plus IFN-α (3000 U/ml; intron A-IFNα2b; Schering-Plough) plus IFN-γ (1000 
U/ml; Endogen) plus polyinosinic-polycytidylic acid (20 μg/ml; Sigma-Aldrich) yielding αDC1; 
2) LPS (250 ng/ml; Sigma-Aldrich) yielding DC.LPS; 3) LPS (250 ng/ml) plus IFN-γ (1000 
U/ml) yielding DC.LPS/IFN; or 4) 1 nM bryostatin-1 (Sigma- Aldrich) yielding DC.BS1 [59]. 
Plastic-nonadherent cells, enriched in T cells, were collected and stored at −80°C for 5–7 days 
during the DC culture period. After thawing, naive or memory T cells were negatively isolated 
using CD45RO or CD45RA MACS microbeads (Miltenyi Biotec), respectively, per the 
manufacturer’s protocols. Isolated cell populations were >98% pure based on corollary flow 
cytometry analyses. In some cases, CD4
+
 or CD8
+
 naive or memory T cell subsets could then be 
further isolated by positive selection using specific MACS beads as indicated. In additional 
experiments, CD45RO
−
 and/or CD45RA
−
 cells were depleted of CD56
+
 cells, or they were 
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separated into their CCR7
+
 vs CCR7
−
 subpopulations using specific MACS beads (Miltenyi), as 
indicated in appendix Fig. 1, 2.   
Recombinant adenoviruses. Human T-bet (hT-bet) was PCR cloned from PBLs using the 
following primers: hT-bet: forward (Fwd) 5′-GTCGACGACGGCTACGGGAAGGTG-3′; 
reverse (Rev) 5′-GGATCCTTAGTCGGTGTCCTCCAACC-3′. The product was then digested 
with the restriction enzymes SalI and BamHI and the 1.7-kb fragment containing full-length hT-
bet was ligated into the adenoviral-Cre-Lox (Ad.lox) vector. After sequence validation, 
recombinant adenoviruses were generated, as previously described [67]. The mock (empty) 
adenoviral vector Ad.ψ5 and/or Ad.EGFP (encoding the enhanced GFP) were used as negative 
controls, as indicated. Adenoviral vectors encoding full-length human IL-12p70 or MART-1 
protein (Ad.MART1) have been previously described [67, 154]. All adenoviruses were 
expanded, purified, and provided by the University of Pittsburgh Vector Core Facility (Shared 
Resource).  
Adenoviral infection of cells. Day 5 immature DC were infected with adenoviruses at a 
multiplicity of infection (MOI) of 300 at 37°C for 48 h as previously described [67]. 293T 
human kidney epithelial cells (American Type Culture Collection; ATCC) were infected with 
Ad.MART1 or Ad.ψ5 at an MOI of 20 for 48 h before being used to generate freeze-thaw cell 
lysates.  
Abs. Abs reactive against T-bet (Santa Cruz Biotechnology), CCR7, CD3, CD4, CD8, 
CD25, CD45RA, CD45RO, CD54, CD70, CTLA-4, IFN-γ, IL-17A, MHC class I, MHC class II 
(BD Biosciences), CD80, CD86, B7-H1, CXCR3, granzyme B, Foxp3, IL-4 (eBioscience), 
CD212, Jagged-1, TGF-βRII (R&D Systems), IFN-γ, IL-4, IL-10 (Miltenyi Biotec), CD11c, 
GITR, GITR-L (BioLegend), DLL4 (Novus Biologicals), MART-1 (Vector Laboratories), or β-
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actin (Invitrogen) were used in flow cytometry, immunofluorescence microscopy, and Western 
blot experiments, as indicated. Anti-HLA-A2 mAbs BB7.2 and MA2.1 (ATCC) and anti-HLA-
DR4 mAb 359-13F10 (a gift from Dr. Janice Blum (Indiana University, Bloomington, IN) were 
used to determine the HLA phenotype of normal donors and melanoma patients based on flow 
cytometry analysis of PBMCs. Neutralizing/blocking anti-human (h) IL-12p70 polyclonal Ab 
(pAb; R&D Systems), anti-IL12Rβ2 pAb (R&D Systems), anti-hIL-23 pAb (R&D Systems), 
anti-IL-27R pAb (TCCR/WSX-1; R&D Systems), anti-hIFN-γ pAb (R&D Systems), anti-hIFN-
γR1 mAb (R&D Systems), anti-CD70 (Ancell), and recombinant human (rh) Notch-1/Fc 
chimera (R&D Systems) were used at final concentrations of 10 μg/ml, per the manufacturers’ 
recommendations.  
Flow cytometry and fluorescence microscopy analyses. Cell surface and intracellular 
staining of cells was performed and monitored by flow cytometry, as previously described [65]. 
For immunofluorescence microscopy, 1 × 10
5
 DCs were cytospun and fixed onto slides. Cells 
were permeabilized and stained with T-bet primary Ab (Santa Cruz Biotechnology) and 
conjugated with goat anti-mouse Alexa Fluor 488 secondary Ab (Invitrogen). The counterstains 
used included Hoechst nuclear dye (Sigma-Aldrich) and F-actin-binding rhodamine phalloidin 
(Invitrogen). Fluorescence images were then captured using an Olympus BX51 microscope 
(Olympus America).  
RT-PCR. For mRNA analysis, DCs were harvested on day 2 (48 h posttransduction), and 
MACS-isolated naive or memory CD4
+
 T cells were harvested on day 3 after initial priming by 
DCs. RNA was isolated with Trizol (Invitrogen). Reverse transcription was performed using 
Moloney murine leukemia virus reverse transcriptase (Applied Biosystems) and random 
hexamers (Applied Biosystems). Semiquantitative PCR was used to amplify cDNA for 
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expression of gene-specific products. Specific primers were used for IL-12p35, IL-12/23p40, IL-
23p19, IL-27p28, EBI-3, IL-15, IL-18, IL-10, TGF-β, IFN-α, and IFN-γ as previously described 
[65]. Additional primer sequences included: T-bet, Fwd 5′-CCACCAGCCACTACAGGATG-3′ 
and Rev 5′-GGACGCCCCCTTGTTGTTT-3′; GATA-3, Fwd 5′-
GTGCTTTTTAACATCGACGGTC-3′ and Rev 5′-AGGGGCTGAGATTCCAGGG-3′; Foxp3, 
Fwd 5′-GCACCTTCCCAAATCCCAGT-3′ and Rev 5′-TAGGGTTGGAACACCTGCTG-3′; 
and RORγt, Fwd 5′-AAATCTGTGGGGACAAGTCG-3′ and Rev 5′-
TGAGGGTATCTGCTCCTTGG-3′. β-Actin primers were used as an internal positive control 
[65].  
Analysis of cytokine production from DCs. To estimate the profile of cytokines 
produced by DCs after cognate DC-T cell interaction, 6 × 10
4
 DCs were cocultured with J558 
CD40L (i.e., CD40L contributes signals normally provided by newly activated T cells) 
expressing fibroblasts for 24 h at a DC:J558 ratio of 1:2 in 96-well flat-bottom plates in 200 μl of 
AIM-V culture medium. Supernatants were collected and stored at −80°C before analysis using 
commercial ELISAs for human IL-12p70, IL-23, TNF-α, and IL-10 (BD Biosciences, except for 
IL-23 ELISA from BenderMedSystems). Additional studies included DC stimulation for 24 h 
using agonists to TLR2 (HKLM; Invivogen) TLR3 (polyinosinic-polycytidylic acid; Sigma-
Aldrich), TLR4 (LPS; Sigma- Aldrich), TLR5 (flagellin; Invivogen), TLR7 (imiquimod; 
Invivogen), as well as a trimeric form of CD40L (a gift from Dr. Andrea Gambotto, University 
of Pittsburgh, Pittsburgh, PA), as indicated.  
Responder T cell proliferation studies (CSFE). The superantigen staphylococcus 
enterotoxin B (SEB) model for priming autologous T cells was used in these studies [155]. 
Briefly, DC.Tbet (ectopic T-bet-expressing DC) or control DC were pulsed with SEB (Sigma-
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Aldrich) at 0.1–10 ng/ml  in AIM-V media (Invitrogen) for 3 h at 37°C prior to washing and the 
addition of 10
4
 DCs to 96-well round-bottom plates. Sorted CD45RO
−
 (naive) or CD45RA
−
 
(memory) T cells were labeled with 0.5 μM CFSE (Invitrogen) in PBS for 15 min at 37°C, 
before being washed twice, with 10
5
 T cells (resuspended in TcMEM (IMDM supplemented with 
10% heat-inactivated human AB serum, L-glutamine, penicillin/streptomycin, and nonessential 
amino acids); all reagents from Invitrogen with the exception of serum (Sigma-Aldrich) added to 
wells containing DCs along with 100 U/ml rhIL-2 (Peprotech). Responder T cells were evaluated 
for CSFE dilution by flow cytometry on day 3 of cocultures.  
Responder T cell polarization studies. T cells were plated with SEB-pulsed DC.Tbet or 
control DC at an E:T ratio of 1:10 in TcMEM. Supernatant of DC-T cell cocultures were 
collected on day 3 and analyzed for hIFN-γ production using a commercial ELISA (BD 
Biosciences). Additionally, on day 3, CD4
+
 T cells were MACS isolated from DC cocultures. 
Total RNA was isolated for RT-PCR analysis or T cells were costained with mAbs to CD4, 
CD212 (IL-12Rβ2), and T-bet for flow cytometric analysis. In additional studies, T cells cultured 
with SEB-pulsed DC.Tbet or control DC on day 0 were restimulated on day 5 with identically 
prepared DC and supplemented with 20 U/ml rhIL-2 (Peprotech) and 5 ng/ml rhIL-7 (Sigma-
Aldrich) every other day. On day 12 or 14 of coculture, T cells were collected and assayed for 
cytokine (IFN-γ, IL-4, IL-17A, and IL-10), cell surface (CXCR3), and intracellular (Foxp3 and 
granzyme B) protein expression by flow cytometry. To evaluate intracellular cytokine 
expression, T cells were stimulated with PMA (1 μg/ml) and ionomycin (50 ng/ml) for 4 h, with 
2 μM monensin (all from Sigma-Aldrich) added over the final 2 h of culture. Where indicated, 
cell culture supernatants were analyzed for secreted levels of hIFN-γ, hIL-4, hIL-10 (all from BD 
Biosciences), and hIL-17A (BioLegend) using commercial ELISAs.  
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Neutralizing/blocking studies. Briefly, DC.Tbet or control DCs were plated with T cells 
at a DC:T cell ratio of 1:10 in triplicate in 96-well flat-bottom plates, in the presence or absence 
of neutralizing/blocking Abs or recombinant fusion protein. On day 3, cell-free supernatants 
were collected and evaluated using a hIFN-γ-specific ELISA. Alternatively, T cells were 
restimulated on day 5 with SEB-pulsed DC and supplemented with rhIL-2, rhIL-7, and 
neutralizing Abs, with T cells harvested on day 14 for analysis of intracellular IFN-γ production 
by flow cytometry.  
Transwell assays. DC.Tbet or control DC (5 × 10
5
) were plated in the bottom chamber of 
a 24-well transwell plate in 400 μl of TcMEM. After 24 h, 1 × 106 naive T cells along with 1 × 
10
5
 SEB pulsed-immature DC or 3 × 10
5
 anti-CD3/CD28 microbeads (Invitrogen) were placed in 
the upper chamber of the transwell plate bringing total volume to 600 μl of TcMEM. Cell 
supernatants were collected from the upper chamber on day 3 for IFN-γ ELISA analyses.  
Generation of lysates containing rMART-1 protein. 293T human kidney epithelial cells 
(ATCC) were infected with Ad.MART1 at an MOI of 20 for 48 h, at which time freeze-thaw 
lysates were generated as previously described [156]. 293T cells infected with Ad.ψ5 (MOI 20) 
were used to generate a negative control lysate. Expression of MART-1 mRNA/protein in 
transduced 293T cells was determined using RT-PCR and immunohistochemistry, and MART-1 
protein in lysates confirmed by Western blot, as previously described [154]. Total lysate protein 
content was estimated by OD280 (1.2 mg = 1.0 OD units full scale at 280 nm), and lysates were 
stored at −80°C until being used to load DCs for T cell induction and recognition assays.  
Analysis of DC processing of recombinant MART-1 protein for recognition by specific 
CD4
+
 T cells. MACS-isolated, naive CD4
+
 T cells were isolated from HLA-DR4
+
 (based on 
monocyte staining with anti-HLA-DR4 mAb 359-13F10 as monitored by flow cytometry) 
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normal donors as outlined above, and stimulated twice on a weekly basis with control DC 
(DC.null) pulsed with the MART-151–73 peptide (10 mM). On day 14 of culture, T cells were 
harvested and assessed for their ability to recognize (in IFN-γ ELISPOT assays) autologous 
DC.null, DCψ5, or DC.Tbet cells prepulsed for 48 h with freeze-thaw lysates (50 μg/ml) 
generated from Ad.MART-1- vs Ad.ψ5-infected 293T cells.  
Ag-specific T cell responses. PBMCs were isolated from healthy, normal donors with 
written consent under an Institutional Review Board-approved protocol. For CD8
+
 T cell 
responses, DCs were generated from HLA-A2
+
 normal donors (i.e., lymphocytes staining with 
both the anti-HLA-A2 mAbs BB7.2 and MA2.1 as monitored by flow cytometry), as outlined 
above, and DC.Tbet or control DC were pulsed with HLA-A2-restricted peptide epitopes 
((EphA2883–891, gp100209–217; 10 μM each)  ref. [157]) for 3 h at 37°C before culturing with 
MACS-isolated naive CD8
+
 T cells at a 10:1 T cell:DC ratio in the presence of 5 ng/ml rhIL-7. 
CD8
+
 T cell cultures were expanded by a second stimulation on day 7 with identically prepared 
DCs or with peptide-pulsed autologous, irradiated PBMCs. Restimulated cultures were 
supplemented with 20 U/ml rhIL-2 and 5 ng/ml rhIL-7, with cytokines replenished every other 
day. On day 14, the frequency of peptide-specific CD8
+
 T cells was analyzed in IFN-γ ELISPOT 
assays (Mabtech) using HLA-A2
+
 T2 cells as APCs that were performed as previously described 
[157]. The HLA-A2-presented HIV-nef190–198 peptide [157] served as a (negative) specificity 
control in these assays. For CD4
+
 T cell responses, DCs were generated from HLA-DR4
+
 normal 
donors (based on monocyte staining with anti-HLA-DR4 mAb 359-13F10 as monitored by flow 
cytometry) as outlined above. DC.Tbets or control DCs were pulsed with 50 μg/ml freeze-thaw 
lysate generated from 293T cells infected with Ad.MART1 vs Ad.ψ5 for 24 h, 37°C and used to 
stimulate autologous MACS-isolated, naive CD4
+
 T cells, as outlined above for CD8
+
 T cell 
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responses. On day 7 of cultures, responder CD4
+
 T cells were restimulated with identically 
prepared, Ag-loaded DCs, and cultures were supplemented with rIL-2 and rIL-7 as noted above. 
On day 14, the frequency of MART-1-specific CD4
+
 T cells was analyzed in IFN-γ and IL-5 
ELISPOT assays (Mabtech) using autologous control DC pulsed with the MART-151–73 vs the 
HIV-nef192–204 (negative) control HLA-DR4-presented peptide epitopes as target cells [158].  
Statistical analyses. A two-tailed Student t test was used for data analysis. Null 
hypothesis was rejected, and differences were assumed to be significant at a value of p < 0.05.  
2.4 RESULTS 
2.4.1 In vitro modulation of T-bet expression in human DCs 
Human DCs were generated from peripheral blood monocytes and transduced with recombinant 
adenovirus encoding human T-bet (DC.Tbet) or control Ad.ψ5 (DC.ψ5 ) for 48 h. DCs were also 
generated using known Type-1 polarizing culture conditions, yielding DC1. Harvested DCs were 
analyzed for T-bet mRNA (via RT-PCR; Fig. 1A) and protein expression (via Western blot and 
flow cytometry; Fig. 1, B and C). As shown in Fig. 1, A–C, T-bet expression in untreated 
immature DC (DC.null) and DC.ψ5  was very low (at both the transcript and protein levels), with 
expression levels augmented in DC.null cells by 24 h of culture in the presence of inflammatory 
stimuli [42, 59, 65]. However, in marked contrast to the <1% frequency of T-bet
+
, DCs 
developed using nonviral culture methods, DC.Tbet were 63 ± 18% T-bet
+
 over 15 independent 
experiments as determined by intracellular staining, as exemplified in Fig. 1C. 
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Immunofluorescence microscopy revealed that T-bet protein was expressed predominantly in the 
nucleus of DC.Tbet cells (Fig. 1D).  
 
 
 
 
 
Figure 1. Generation and characterization of DC.Tbets 
Immature DCs were generated from peripheral blood monocytes by culturing with IL-4 and GM-CSF for 5–6 days. 
DC were left untransduced (DC.null) or transduced with recombinant adenoviral vectors containing an empty 
cassette (Ad.ψ5), human T-bet (Ad.Tbet), or hIL-12p70 (Ad.IL12), yielding DC.ψ5, DC.Tbet and DC.IL12 cells, 
respectively. A, DC.null, DC.ψ5 , DC.Tbet, and DC.IL12, as well as DCs activated for 24 h in the presence of 
inflammatory stimuli (i.e., yielding αDC1, DC-LPS/IFN, and DC.BS1 as described in Materials and Methods) were 
analyzed for T-bet vs control β-actin mRNA expression by RT-PCR. In B and C, the indicated DC populations were 
analyzed for T-bet protein expression by Western blotting and intracellular immunofluorescence staining monitored 
by flow cytometry, respectively. D, Confocal immunofluorecence microscopic images of the indicated DC 
populations stained for expression of T-bet [147], phalloidin (Red), and 4′,6′-diamidino-2-phenylindole (DAPI; 
blue). Data are representative of at least three independent assays performed for each panel.  
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2.4.2 DC.Tbet selectively prime CD45RO- (naïve) T cells toward Type-1 polarization in 
vitro 
Given previous reports that intrinsic (low-level) expression of T-bet in DC is crucial to the 
ability of these APC to promote Type-1 T cell responses [144, 151-153], we hypothesized that 
DC.Tbet cells might be enhanced in this capacity. We used a superantigen (SEB) model to 
investigate DC.Tbet-induced specific responses from naive vs memory T cell populations in 
vitro. Briefly, DC.Tbet or control DCs were pulsed with 1 ng/ml SEB before coculture with 
autologous naive (MACS-isolated CD45RO
−
 cells) or memory (MACS-isolated CD45RA
−
) bulk 
(CD4
+
 and CD8
+
) T cells at a DC:T cell ratio of 1:10 for 72 h. These conditions were chosen 
based on dilutional analyses in which optimal IFN-γ was observed from responder T cells within 
both the control DC- and DC.Tbet-stimulated cohorts at an SEB dose of 1 ng/ml.  
As shown in Fig. 2A, IFN-γ production from activated naive, but not memory, bulk 
(CD4
+
 and CD8
+
) T cells was significantly up-regulated when primed by SEB-pulsed DC.Tbet 
vs SEB-pulsed control DC (p = 0.004). Macroscopically, DC.Tbet-activated cultures developed 
from naive, bulk T cell precursors contained very large cellular clusters (Fig. 2B), suggestive of 
differentially enhanced T cell proliferation within such cultures. However, a repeated series of 
assays implementing bulk CD45RO
−
 vs CD45RA
−
 T cells that were prelabeled with 0.5 μM 
CFSE before coculture with control DCs or DC.Tbet, revealed no significant changes in the 
frequencies of daughter cell generations (CD45RO
−
 T cells; Fig. 2, C and D) or T cell yields on 
day 3 or 7 of culture (Fig. 2C), although the enhanced ability of daughter T cells to produce IFN-
γ in DC.Tbet (+ CD45RO− bulk T cell) cocultures was readily apparent (Fig. 2D). This latter 
increase was evident in both the percentage of IFN-γ+CSFElow+ events (Fig. 2D) and the 
approximate doubling in mean fluorescence intensity levels for IFN-γ expression in responder T 
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cells (157 for DC.Tbet cultures vs 73 or 71 for DC.null or DC.ψ5 cultures, respectively; data not 
shown). These data strongly suggest that DC.Tbets enhance Type-1 responses from bulk, 
CD45RO
−
 T cells via differential polarizing, rather than proliferative, signals.  
To exclude the potential impact of contaminant NK/NKT cells on the IFN-γ level 
observed in the in vitro stimulation assay, we MACS-isolated CD45RO
−
CD56
−
 T cells (appendix 
Fig. 1) and repeated our the assay using autologous SEB-pulsed DC.Tbets vs control DCs as 
APCs. As shown in appendix Fig. 1B, depletion of CD56
+
 cells from CD45RO
−
, bulk T cell 
responders did not inhibit the ability of DC.Tbets to promote superior IFN-γ production. Next, 
we further define T cell functional subsets into naive (CD45RO
−
CCR7
+
CD62L
+
), effector (TE; 
CD45RO
−
CCR7
−
CD62L
dim+
 or CD45RA
−
CCR7
−
CD62L
dim+
), central memory (TCM; 
CD45RA
−
CCR7
+
CD62L
+
) and effector memory (TEM; CD45RA
−
CCR7
−
CD62L
dim+
) 
subpopulations based on MACS isolation and flow staining. Only naive T cells that were highly 
enriched (∼90% pure) for the CCR7+CD62L+ phenotype exhibited differential responsiveness to 
DC. Tbets (vs control DCs) based on a substantial up-regulation in their production of IFN-γ 
(appendix Fig. 2B). This result proved that DC.Tbet preferentially support type 1 development of 
naive (CD45RO
−
CCR7
+
CD62L
+
), but not memory, T cell precursors. 
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Figure 2.  DC.Tbets uniquely promote IFN-γ responses from naïve bulk T cells in vitro 
Bulk, naive (CD45RO
−
), or memory (CD45RA
−
) T cells were isolated by negative selection and cultured with 
autologous, SEB-pulsed DC.Tbets or control DCs at a ratio of 10:1, respectively. After 72 h, supernatants were 
collected for analysis using IFN-γ ELISA (A; ∗, p < 0.05 vs DC.null or DC.ψ5), and the cocultures were assessed 
under bright-field microscopy (×10; B). Identical cultures using CFSE-labeled T cells (gated on CD3
+
 cell 
populations) were analyzed for CFSE dilution based on daughter-cell generation by flow cytometry and quantitated 
for cell yield (on days 3 and 7 of culture) in C. D, Intracellular expression of IFN-γ in CFSE-labeled T cells was 
evaluated after 72 h of coculture with DC.Tbets vs control DCs. All data are representative of three independent 
assays performed.  
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2.4.3 DC.Tbet priming suppresses the generation of type 2 and Tregs from naïve 
precursors 
To further assess responder T cell polarization status, we isolated CD3
+
 T cells from DC-bulk T 
cell cocultures after 72 h and analyzed these cells for their comparative expression of mRNAs 
encoding trans activator proteins (i.e., T-bet (Th1), GATA-3 (Th2), RORγt (Th17), and Foxp3, 
as Treg) linked to T cell function (Fig. 3A). We observed that naive T cells stimulated with 
DC.Tbet cells were enriched (∼5-fold as assessed by densitometry analysis of gel bands; data not 
shown) in T-bet, and reduced in GATA-3 (∼4-fold), RORγt (<2-fold) and Foxp3 (∼5-fold) 
transcripts when compared with T cells stimulated with control DCs (Fig. 3A). To corroborate 
these findings at the protein level, we assessed the polarization state of responding CD4
+
 T cells 
by analyzing their cytokine production profiles. We confirmed reductions in the levels of IL-4 
and IL-10 produced by naive (but not memory) T cells stimulated with autologous SEB-pulsed 
DC.Tbet (vs control DC; p < 0.05) as analyzed in ELISA and intracellular staining protocols 
(bulk cells analyzed in Fig. 3B and CD3
+
 T cells assessed in Fig. 3C, respectively). Also, the 
frequency of responder CD4
+
Foxp3
+
 T cells was reduced after activation of naive (but not 
memory T cells) with SEB-pulsed DC.Tbets vs control DCs (Fig. 3D). In slight contradiction to 
the RT-PCR data reported for ROR-γt in Fig. 3A, we noted a modest increase in IL-17A protein 
production from naive T cells primed using DC.Tbets vs control DCs (Fig. 3B and C).  
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Figure 3.  DC.Tbets selectively prime naive, bulk T cells toward Type-1 polarization in vitro 
Bulk CD45RO
−
 or CD45RA
−
 T cells were stimulated with autologous, SEB-pulsed DC.Tbets vs control DCs as 
described in Fig. 2A. A, CD3
+
 T cells were MACS isolated from the CD45RO
−
 cocultures and RT-PCR performed 
to analyze relative Tbet, GATA-3, Foxp3, RORγt, and β-actin transcript levels. B, Day 3 coculture supernatants 
harvested from bulk T cell-DC cocultures were analyzed for levels of IL-4, IL-17A, and IL-10 by specific ELISA. ∗, 
p < 0.05 for DC.Tbet vs DC.null or DC.ψ5. C, Day 3 responder CD3+ T cells MAC isolated from cocultures 
initiated using CD45RO
−
 responder cells were analyzed for intracellular IFN-γ, IL-4, IL-17A, and IL-10 by flow 
cytometry as outlined in Materials and Methods. D, Cocultures were restimulated on day 5 with DC.Tbets or 
control DCs (as outlined in Materials and Methods) and CD4
+
 T cells MACS isolated for analysis of intracellular 
expression of Foxp3 by flow cytometry on day 14 (when Foxp3 expression is expected to be retained only in Treg 
and nonactivated, non-Treg cells). All data are representative of three independent assays performed.  
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2.4.4 DC.Tbet are suppressed in the secretion of IL-12 family cytokines and IFN-γ 
The ability of DC.Tbets to selectively augment Type-1 responses from naive T cells initially 
suggested the likely involvement of DC-produced IL-12 family members such as IL-12p70, IL-
23, and IL-27 [139-141, 159]. We found that although DC.Tbets expressed reduced levels of IL-
27p28 mRNA, transcript levels for all other IL-12- and IL-23-associated mRNAs, as well as a 
number of alternate DC-associated cytokines were unchanged in DC.Tbets vs control DCs (Fig. 
4A). Strikingly, despite DC.Tbet exhibiting an essentially control DC cytokine mRNA profile, 
these APCs were profoundly suppressed (vs control DCs) in their capacity to secrete any 
cytokine evaluated (i.e., IL-12p70, IL-23, TNF-α, and IL-10) either spontaneously or in response 
to CD40 ligation or TLR stimulation (Fig. 4B and 4C). Consistent with the lack of expression of 
IFN-γ mRNA in any DC population analyzed in Fig. 4A, IFN-γ was not produced at detectable 
levels by any of the DC cohorts (i.e., <4.7 pg/ml as determined by specific ELISA; data not 
shown). Additional analyses suggest that the inability of DC.Tbets to produce these cytokines 
was not the result of reduced DC vitality or enhanced sensitivity of these APCs to apoptosis vs 
control DC.  
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DC.Tbet vs control DCs were analyzed for levels of the indicated cytokine mRNA (using RT-PCR in A) and 
secreted cytokines (using specific ELISA in B, C) upon CD40 ligation or TLR ligands stimulation. As outlined in 
Materials and Methods. ∗, p < 0.05 vs DC.null and DC.ψ5 controls. All data are representative of three independent 
assays performed. 
 
Figure 4. DC.Tbet are suppressed in their capacity to secrete cytokines in 
response to CD40 ligation or TLR ligands when compared with control DCs 
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2.4.5 DC.Tbet promote Type-1 T cell development via a novel mechanism that is largely 
independent of IL-12 while requires close DC-T cell proximity 
Despite low levels of cytokine production by DC.Tbets, we evaluated whether IL-12 family 
member cytokines (or IFN-γ itself) were involved in the priming of Type-1-polarized T cell 
responses by SEB-pulsed DC.Tbets vs control DCs. In vitro stimulations of naive, bulk T cells 
were recapitulated in the absence or presence of neutralizing/blocking Abs reactive against IL-
12p70, IL-23, IL12Rβ2, IL27R, and/or IFN-γ (Fig. 5, A–C). IFN-γ production by T cells primed 
by all control DC populations (including DC/IFN, DC/IFN plus LPS, and anti-DC1) was clearly 
dependent on IL-12p70 and/or IFN-γ itself, as well as a functional IL-12Rβ2-dependent 
signaling pathway. However, this was not the case for naive, bulk T cells activated using 
DC.Tbet cells. Indeed, antagonism of these cytokines/cytokine receptors did not significantly 
affect the ability of DC.Tbets to prime Type-1 T cell responses in vitro (Fig. 5, A–C).  
Because RT-PCR and ELISA analyses suggested the coordinate silencing of cytokine 
secretion by DC.Tbet, this implicated the likely dominant involvement of cell membrane 
interactions rather than soluble mediators in the differential ability of DC.Tbet to drive Type-1 T 
cell responses in vitro. We confirmed this hypothesis by coculturing CD45RO
−
, bulk T cells with 
anti-CD3/CD28 mAb-coated beads or with SEB-pulsed control DC in the upper chambers of 
transwell plates, with DC.Tbets or control DCs placed in the lower chambers. After 72 h of 
culture, supernatants harvested from the various T cell cultures were all found to contain 
comparable levels of IFN-γ (Fig. 5D), suggesting that physical separation of DC.Tbets from 
responder T cells mitigates their capacity to promote superior Type-1 immunity in vitro.  
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Figure 5. DC.Tbet induction of Type-1 immunity from naive T cell responders is independent of IL-
12 family member cytokines and requires DC.Tbet-T cell contact or their close proximity 
DC-naive T cell cocultures were established as outlined in Fig. 2 using SEB-pulsed, autologous DC.Tbet, culture-
conditioned DC (i.e., DC.IFN, DC.IFN/LPS or αDC1 as described in Fig. 1 and Materials and Methods) or control 
DC as APC. Cocultures were developed in the absence or presence of control IgG or neutralizing/blocking anti-
IL12p70 (A), anti-IL-12p70, anti-IL23 or anti-IL-27R pAbs (B), or anti-IL12p70, anti-IL12Rβ2 and/or anti-IFN-γ 
pAbs (C). In A–C experiments, cell-free supernatants were harvested after 72 h of DC-T cell coculture and levels of 
IFN-γ determined using a specific ELISA. ∗, p < 0.05 vs control IgG. D, Transwell assays were performed as 
described in Materials and Methods, with culture supernatants analyzed for levels of IFN-γ via ELISA. All data are 
reported as the mean ± SD of triplicate well determinations and are representative of at least three independent 
assays performed using different donors. 
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2.4.6 DC.Tbet promotes superior tumor Ag-specific, Type-1 CD4+ and CD8+ T cell 
responses in vitro  
To determine whether DC.Tbets were capable of promoting enhanced Tc1 immunity against 
tumor Ags (such as EphA2 and gp100. as in Ref.[42]), naive CD8
+
 T cells were isolated from 
HLA-A2
+
 normal donors and then cocultured with autologous DC.Tbets or control DCs pulsed 
with an equimolar mixture of the EphA2883–891 and gp100209–217(2M) peptides. T cells were 
restimulated after 7 days of culture and then assessed for populational frequencies of peptide-
specific, IFN-γ-producing CD8+ T cells on day 14. We observed that T cell cultures primed 
using DC.Tbets (vs control DCs) contained significant increases in their frequencies of Type-1 
CD8
+
 T cells reactive against both the EphA2 and gp100 peptides, but not a negative control 
HIV-nef peptide epitope (Fig. 6A). We observed elevated Ag-specific responses for the 
DC.Tbet-primed cohort of CD8
+
 T cells regardless of whether peptide-pulsed autologous 
DC.Tbets or PBMCs were used as APCs in the restimulation phase of this experiment (Fig. 6A). 
This supports the likelihood that the dominant impact of DC.Tbet on specific Tc1 responses 
occurs during the priming phase.  
To address whether DC.Tbet were similarly capable of promoting improved TH1 
responses against a tumor Ag, we initially showed that these APCs were fully competent to 
uptake and process exogenous recombinant MART-1 protein (in the form of a freeze-thaw lysate 
of 293T previously transduced with a recombinant adenovirus encoding hMART-1) and then 
present the derivative HLA-DR4-presented MART-151–73 epitope [160] to a peptide-specific 
CD4
+
 T cell line. To determine whether MART-1 protein-pulsed DC.Tbet cells were competent 
to preferentially prime Type-1 responses from naive CD4
+
 T cell responders, DC.Tbets and 
control DCs were loaded with 293T.MART1 lysate for 24h and then used to prime and boost (on 
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day 7 of culture) autologous, naive CD4
+
 T cells isolated from normal HLA-DR4
+
 donors. As 
shown in Fig. 6B, CD4
+
 T cells analyzed on day 14 of culture displayed superior levels of 
reactivity against the MART-151–73 peptide epitope in IFN-γ (and reduced specific responses in 
IL-5) ELISPOT assays using autologous DC.nulls as APCs if they had been developed using 
MART-1
+
 lysate-pulsed DC.Tbet vs control DC (p < 0.05).  
 
Figure 6. DC.Tbet promotes superior tumor Ag-specific priming of Type-1 T cell responses from 
naive CD8
+
 T cell precursors in vitro 
A, HLA-A2
+
 DC.Tbet or control (untreated of DC.ψ5) DC were pulsed with the HLA-A2-presented tumor-
associated peptides EphA2883–891 and gp100209–217(2M) and used to stimulate autologous, MACS-isolated, naive CD8
+
 
T cells. Responder T cell cultures were restimulated with identically prepared (peptide-pulsed, autologous) DC or 
control PBMC on day 7, with restimulated cultures supplemented with rhIL-2 and rhIL-7 (as outlined in Materials 
and Methods). On day 14 of culture, Ag-specific TC1 responses were assessed in IFN-γ ELISPOT assays using 
HLA-A2
+
 T2 cells as APC for relevant (EphA2, gp100) vs irrelevant (HIV-nef190–198 negative control) peptides. 
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Data are representative of one of three independent normal HLA-A2
+
 donors evaluated. B, Naive, CD4
+
 T cells were 
isolated from the peripheral blood of HLA-DR4
+
 normal donors and stimulated on days 0 and 7 with autologous 
DC.Tbet or control DC that had been pre-pulsed for 24 h with a freeze-thaw lysate generated from HLA-
DR4
−
MART-1
−
 293T human kidney epithelial cells infected with either Ad.MART-1 or Ad.ψ5 control virus (MOI 
20 for 24 h at 37°C). On day 14 of cultures, responder CD4
+
 T cells were analyzed in 24-h IFN-γ ELISPOT assays 
for reactivity against autologous DC.null cells pulsed with either the HLA-DR4-presented MART-151–73 peptide 
epitope or the negative control HLA-DR4-presented HIV-nef192–204 peptide epitope. Representative data is depicted 
for 1 of 2 independent normal HLA-DR4
+
 donors evaluated. In both A and B, data are reported as the mean ± SD of 
triplicate assay determinations; ∗, p < 0.05 vs DC.null or DC.ψ5.  
2.5 DISCUSSION 
The transcription factor T-bet was originally identified as a master regulator of Th1 development 
but has since been found to differentially regulate genes in CD8+ effector T cells, B cells, and 
NK and NKT cells [50, 51, 53]. In particular, Glimcher et al. [4, 50] have shown that 
endogenous expression of T-bet in DCs is necessary for optimal induction of Type-1 T cell 
responses. A major finding in the current studies is that ectopic (over)expression of T-bet (as a 
result of recombinant adenoviral T-bet cDNA delivery) to license DC to preferentially support 
the in vitro development of Type-1 (over type 2 and Treg) polarized responses from naive 
(CD45RO−CCR7+CD62L+), but not memory, T cell precursors. Preferential enhancement in 
Type-1 T cell development was reflected at the level of differential trans activator molecule 
mRNA expressed (with T-bet increased and GATA-3, as well as Foxp3 being decreased) and 
cytokines secreted (with IFN-γ increased, and IL-4 as well as IL-10 being decreased). 
Furthermore, levels of cell surface (CXCR3, IL-12Rβ2) and effector (granzyme B, IFN-γ) 
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molecules associated with Type-1 functionality were increased in naive T cells after specific 
activation with DC.Tbets vs control DCs. Although, ROR-γt mRNA transcripts appeared 
unaffected or, in some cases, somewhat reduced in naive T cells primed with DC.Tbets vs 
control DCs, we found that the level of IL-17A secreted by these responder T cells tended to be 
modestly increased (p < 0.05 vs control DC-stimulated T cells). This may not be too surprising 
due to the mutual functional exclusivity between Foxp3+ Treg (suppressed after DC.Tbet 
stimulation) and Th17 T cells (potential compensatory enhancement), as previously reported by 
others [161]. Furthermore, we did not detect Th17 cells coproducing both IFN-γ and IL-17A 
(Fig. 3C), suggesting that IFN-γ analyzed in our studies is stringently associated with bona fide 
Type-1 T cell responses.  
A second major finding in our work relates to the IL-12 cytokine family-independent 
mechanism(s) involved in DC.Tbet activation of Type-1 CD4
+
 and CD8
+
 effector cells from 
naive T cells. Indeed, we noted that 1) production of IL-12p70, IL-23, and IL-27, as well as all 
other cytokines evaluated, was suppressed in DC.Tbets vs control DCs and 2) neutralizing Abs 
against IL-12p70, IL-23p19, IL-12Rβ2, and IL-27R all failed to attenuate DC.Tbet-mediated 
induction of Type-1 responses from naive T cells. It remains formally possible that the absence 
of cytokine (i.e., IL-23 and IL-27)-mediated signaling into T cells could reinforce their Type-1 
functional polarization, as others have previously shown that 1) IL-27 mediates the 
differentiation of naive T cells into IL-10 producing Tr1 cells [162] and 2) signals mediated via 
the IL-23R are crucial for the development of TH17 responses [163].  
Results obtained in transwell assays support the critical importance of DC.Tbet-T cell 
interaction or proximity in order for Type-1 polarizing signals to be conveyed during the T cell 
priming event. Yet a survey of DC surface molecules for expression levels revealed no striking 
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differences between DC.Tbet and control DC.ψ5 (or DC.EGFP) for MHC molecules, integrins, 
co-stimulatory/inhibitory molecules or modulatory receptors (appendix Fig. 3). CD70 and 
NOTCH ligands δ-like-4 and Jagged-1 which have been previously shown to contribute to the 
functional polarization of responder T cells by DCs [142, 143, 164], were not expressed (or 
expressed poorly) by DC.Tbet (appendix Fig. 4A), and appeared functionally irrelevant in our 
model system since the inclusion of specific blocking reagents had no perceptible impact on the 
ability of DC.Tbet to support enhanced Type-1 responses from CD45RO
−
, bulk T cells 
(appendix Fig. 4B).  
Overall, our data appear to support a novel mechanism by which DC.Tbet preferentially 
prime Type-1 T cell responses from naive T cell precursors. This is manifest in enhanced DC-
naive T cell clustering at early phases of the induction process (i.e., day 3) via a process that was 
not correlated with T cell proliferation/expansion based on CFSE dilution analyses in vitro. 
These data could suggest that DC.Tbet-naive T cell interactions may be uniquely prolonged due 
to the sustained interfacing of key MHC/TCR and costimulatory/integrin/adhesion molecules 
and/or to the abbreviated impact of coinhibitory or intercellular repulsion molecules  [165-168], 
resulting in a reinforced commitment of newly primed T cells toward a state of Type-1 
functional polarization. It is also possible that DC.Tbets may be refractory to dissociating 
signals, such as those contributed via newly activated T cell-expressed CTLA-4 [169]. If such 
interactions underlie the observed selective priming of Type-1 immunity by DC.Tbets, this could 
explain the inability of DC.Tbet to affect superior Type-1 responses from the activated, memory 
T cell population, given that memory T cells are known to exhibit a lower activation threshold 
requirement for both signal 1 (MHC/peptide) and signal 2 (costimulation) when compared with 
naive T cells [170]. We are currently pursuing a further characterization (genomic, proteomic) of 
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changes occurring in DC.Tbet that may be implicated in the selective priming Type-1 responses 
from naive T cells.  
Type-1 T cell responses appear most efficient in regulating disease development and 
progression in the cancer setting [65, 67, 154, 155, 171, 172]. Hence, the ability to predictably 
generate tumor-specific Type-1 immunity is a major target for cancer immunotherapy-based 
approaches. A means to accomplish this goal includes the use of vaccines that may selectively 
and predictably augment the development of Tc1 and Th1 effector T cell populations. Although 
such vaccines have commonly integrated autologous DCs as a biological adjuvant [127, 154, 
171] over the past decade, significant heterogeneity in DC subsets and variable states of 
maturation have yielded equivocal results in both preclinical tumor models and clinical trials 
applying DC-based modalities [127].  
In this context, methods to condition or engineer DC1 that are particularly competent to 
expand and develop Type-1 T cell-mediated antitumor immunity may improve clinical efficacy 
of DC-based cancer vaccines. In this regard, (IL-12p70-independent) DC.Tbets promote at least 
equitable Type-1 T cell responses to (IL-12p70-dependent) αDC1, a current gold standard for 
clinically applied DC1 [42]. Given the apparent non-overlapping mechanism of Type-1 immune 
induction by DC.Tbets and IL-12p70, it might be envisioned that these two agents might act 
synergistically in promoting Tc1 and Th1 responses. We are currently evaluating this possibility 
in vitro.  
Our in vitro stimulation experiments using tumor peptide (i.e., EphA2 and gp100) or 
protein (recombinant MART-1)-pulsed DC.Tbets clearly support the improved capacity of this 
vaccine to promote specific Tc1 and Th1 responses in vitro from naive CD8
+
 and CD4
+
 T cells, 
respectively. Such Type-1 T cells would be predicted to be competent to both infiltrate tumor 
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lesions (as associated increases in CXCR3 expression are observed) in vivo [64, 159] and to 
mediate robust antitumor activity within these sites [173]. Furthermore, because DC.Tbets retain 
their capacity to uptake whole (tumor) proteins and to process and then prime tumor Ag-specific, 
Type-1 CD4
+
 and CD8
+
 T cell responses in vitro, they may also be envisioned as a therapeutic 
modality to be injected directly into tumor lesions in vivo (where they may acquire and then 
preferentially prime Type-1 antitumor T cell responses). Overall, the potent capacity of DC.Tbet 
to promote Ag-specific Type-1 T cell responses while coordinately minimizing type 2/Treg 
functional responses suggests that (DC.Tbet-based) vaccines may yield enhanced therapeutic 
efficacy in vivo [174] in the settings of cancer and infectious disease.  
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3.1 ABSTRACT 
T-bet (Tbx21), a T-box transcription factor, has been previously identified as a master regulator 
of Type-1 T cell polarization. We have also recently shown that the genetic engineering of 
human dendritic cells (DCs) to express human T-bet cDNA yields Type-1-polarizing APCs in 
vitro [175]. In the present study, murine CD11c+ DCs were transduced with a recombinant 
adenovirus encoding full-length murine T-bets (DC.mTbets) and analyzed for their 
immunomodulatory functions in vitro and in vivo. Within the range of markers analyzed, 
DC.mTbets exhibited a control DC phenotype and were indistinguishable from control DCs in 
their ability to promote allogenic T cell proliferation in MLR in vitro. However, DC.mTbets 
were superior to control DCs in promoting Th1 and Tc1 responses in vitro via a mechanism 
requiring DC–T cell interaction or the close proximity of these two cell types and that can only 
partially be explained by the action of DC-elaborated IL-12p70. When injected into day 7 s.c. 
CMS4 sarcoma lesions growing in syngenic BALB/c mice, DC.mTbets dramatically slowed 
tumor progression (versus control DCs) and extended overall survival via a mechanism 
dependent on both CD4+ and CD8+ T cells and, to a lesser extent, asialoGM1+ NK cells. 
DC.mTbet-based therapy also promoted superior tumor-specific Tc1 responses in the spleens and 
tumor-draining lymph nodes of treated animals, and within the tumor microenvironment it 
inhibited the accumulation of CD11b+Gr1+ myeloid-derived suppressor cells and normalized 
CD31+ vascular structures. These findings support the potential translational utility of DC.Tbets 
as a therapeutic modality in the cancer setting.  
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3.2 INTRODUCTION 
Dendritic cells (DCs) play important roles in regulating the magnitude and nature of specific T 
cell responses that underlie effective cancer immunotherapy [34, 36, 176, 177]. In particular, the 
state of DC polarization may determine, in turn, the biased polarization of functional T cell 
responses [42], with Type-1 T cell-mediated immunity commonly linked with superior anti-
tumor efficacy in vivo [178]. Recent attention has been focused on defining means by which to 
condition or engineer DCs to attain so-called DC1s that license Type-1 T cell-mediated 
immunity [178, 179]. 
In this regard, combinations of proinflammatory cytokines and TLR ligands have been 
demonstrated to yield DC1-like APCs producing high levels of IL-12p70 and eliciting robust 
Tc1/Th1 T cell responses in vitro [180]. Such conditioned DC1s are now being translated into 
phase I clinical trial designs for the treatment of patients with various forms of cancer [65, 181].  
Alternatively, DCs have been engineered with cDNA encoding Type-1-polarizing 
cytokines, such as Type-1 and type 2 IFNs, IL-12p70 and IL-18 [66, 177, 182], among others, 
again yielding APCs with improved competence to drive and sustain Th1 and Tc1 immunity in 
vitro and/or in vivo. We have also recently demonstrated that infection of human DCs with a 
recombinant adenovirus encoding human T-bet, a transactivator protein associated with Type-1 
polarity in T effector cells, results in these APCs attaining DC1 status in vitro [175]. 
Interestingly, these human DC.Tbets promote polarized Type-1 T cell responses via a 
mechanism that appears independent of secreted cytokines (including IL-12p70), but dependent 
on the DC–T cell interaction or the close approximation of these two cell types.  
The present studies were performed to assess whether murine DCs engineered to express 
murine T-bet (mT-bet) exhibited comparable DC1 functionality in vitro and in vivo when 
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injected directly into tumor lesions in a murine sarcoma model. We report that DCs infected with 
recombinant adenovirus encoding mT-bet (DC.mTbets) mediate anti-tumor activity in vivo via 
the enhanced activation of anti-tumor Tc1 cells and the normalization of myeloid-derived 
suppressor cell (MDSC) levels and the vasculature within the tumor microenvironment (TME).  
3.3 MATERIALS AND METHODS 
 
Mice. Female 6- to 8-wk-old C57BL/6 (H-2
b
) and BALB/c (H-2
d
) mice were purchased from 
The Jackson Laboratory (Bar Harbor, ME). All animals were handled under aseptic conditions 
per an Institutional Animal Care and Use Committee-approved protocol and in accordance with 
recommendations for the proper care and use of laboratory animals.  
Cell lines and culture. As previously described, MethA and CMS4 are chemically 
induced sarcomas that are syngenic to BALB/c mice [183]. These cell lines were free of 
Mycoplasma contamination and were maintained in complete medium (CM; RPMI 1640 
medium supplemented with 10% heat-inactivated FBS, 100 μg/ml streptomycin, 100 U/ml 
penicillin, and 10 mmol/l L-glutamine; all reagents were purchased from Invitrogen, Carlsbad, 
CA) at 5% CO2 tension in a 37°C humidified incubator. For T cells culture, 50 μM 2-ME 
(Sigma-Aldrich, St. Louis, MO) was added to CM.  
Adenoviral vectors. E1/E3-substituted, replication-defective adenoviruses were 
constructed through Cre-lox recombination [184]. For recombinant adenovirus encoding mT-bet 
(Ad.mT-bet) construction, cDNA encoding full-length mouse T-bet (amino acids 1–530) was 
excised from the pcDNA3.1-mT-bet plasmid (provided by Dr. L. Glimcher, Harvard University, 
 52 
Boston, MA) [3] using the restriction enzyme EcoRI, with the isolated cDNA then ligated into an 
EcoRI cloning site in the pAdLox shuttle vector [184], yielding pAdlox.mT-bet. After sequence 
validation of the plasmid, recombinant Ad.mT-bet was generated by cotransfection of 
pAdLox.mT-bet and ψ5 helper virus DNA into the adenoviral packaging cell line CRE8 [184]. 
Ad.mT-bet was purified from specific CRE8 lysates by cesium chloride density-gradient 
centrifugation and subsequent dialysis before storage in 3% threalose at −80°C. Titers of viral 
particles were determined by optical densitometry. The empty E1/E3-substituted, replication-
defective adenoviral vector (Ad.ψ5) was used as negative control vector in all studies, as 
previously described [184, 185].  
Generation of bone marrow-derived DCs and transduction with adenoviral vectors in 
vitro. DCs were generated from the tibias/femurs of BALB/c mice, as previously described 
[177]. Briefly, bone marrow precursors were cultured for 7 d in CM supplemented with 1000 
U/ml recombinant murine (rm)GM-CSF and 1000 U/m rmIL-4 (both from Peprotech, Rocky 
Hill, NJ). CD11c
+
 DCs were then purified using specific MACS beads (Miltenyi Biotec, Auburn, 
CA) and infected with recombinant adenovirus (either Ad.ψ5 or Ad.mT-bet) at a multiplicity of 
infection (MOI) of 250 for 48 h. Intracellular staining and flow cytometry were used to 
document expression of mTbet in Ad-infected DCs.  
CMS4 therapy model. BALB/c mice received s.c. injection with 5 × 10
5
 CMS4 tumor 
cells in the right flank on day 0. On day 7, mice were randomized into treatment cohorts (five 
mice each) exhibiting comparable mean tumor sizes (i.e., ∼40 mm2). Control DCs (DC.nulls or 
DC.ψ5 s) or DC.mTbets (106) were then injected intratumorally (i.t.) in a total volume of 50 μl 
(in PBS) on days 7 and 14 posttumor inoculation. Tumor size was assessed every 3 or 4 d and 
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recorded in mm
2
 by determining the product of the largest perpendicular diameters measured by 
vernier calipers.  
In vivo immune cell subset depletion. On days 6, 13, and 20 after tumor inoculation, 
mice were injected i.p. with purified Abs: 50–100 μg rat isotype control Ab (Sigma-Aldrich), 50 
μg anti-CD4 mAb GK1.5 (American Type Culture Collection, Manassas, VA), 100 μg anti-CD8 
mAb3-6.7 (provided by Dr. Zhaoyang You, University of Pittsburgh), or 50 μl anti-asialoGM1 
polyclonal Ab (pAb; to deplete NK cells; Wako, Osaka, Japan). Ab-mediated depletion was 
>95% effective for the targeted immune cell subset based on flow cytometry analysis of 
peripheral blood monuclear cells obtained by tail venipuncture from treated mice 24 h after Ab 
administration (data not shown).  
Flow cytometry. Control and Ad-infected DCs were stained with the following Abs and 
their corresponding isotype controls: PE- or FITC-conjugated mAbs reactive against the mouse 
cell surface molecules H-2K
d
, H-2-IA
d
, CD11c, CD40, CD54, CD80, CD86 (all mAbs from BD 
Biosciences, San Diego, CA). After incubation for 30 min at 4°C in the dark, DCs were washed 
twice with FACS buffer (0.1% BSA and 0.05% sodium azide in PBS) before being analyzed by 
flow cytometry. Control and DC.mTbets viability was also analyzed after staining cells with 7-
aminoactinomycin D and annexin V-FITC (both from BD Biosciences, San Jose, CA) as 
previously described [175]. All flow analysis was performed using a FACScan flow cytometer 
and CellQuest software (BD Biosciences).  
Western blotting. DC.nulls and gene-modified DCs (DC.ψ5 s or DC.mTbets) were 
harvested after 48 h of transduction by adenovirus vectors. Western blotting was then performed 
as previously described [186]. Briefly, harvested cells were incubated with lysis buffer (1% 
Triton X-100, 10 mmol/l Tris-HCl [pH 7.4], 1 mmol/l EDTA, 150 mmol/l NaCl, 0.2 mmol/l 
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sodium orthovanadate, 0.5% Nonidet P-40 in PBS; all reagents from Sigma-Aldrich) containing 
a protease inhibitor mixture (Complete Mini; Roche Diagnostic Systems, Indianapolis, IN) for 30 
min on ice. After centrifugation at 13,500 × g for 30 min, the supernatant was mixed 5/1 with 
SDS-PAGE running buffer, and proteins were separated on 10% PAGE gels. mAbs against T-bet 
and HRP-conjugated goat anti-mouse Ab (both from Santa Cruz Biotechnology, San Diego, CA) 
were used to detect the expression of T-bet. β-actin was subsequently detected with rabbit anti-
actin Ab (Abcam, Cambridge, MA) and HRP-conjugated goat anti-rabbit Ab (Santa Cruz 
Biotechnology) as an internal control. Probed proteins were visualized by a Western Lightning 
chemiluminescence detection kit (PerkinElmer, Waltham, MA) and exposed to X-Omat film 
(Eastman Kodak, Rochester, NY).  
Evaluation of CD8
+
 T cell responses against CMS4 tumors ex vivo.  For in vitro 
stimulation cultures, spleens were harvested from two mice per cohort 7 d after the second i.t. 
injection with adenoviral-transduced DCs (i.e., day 21 after tumor inoculation), and pooled 
splenocytes (2 × 10
6
 cells/well) were stimulated with irradiated (100 Gy) CMS4 cells (2 × 10
5
 
cells/well) in the presence of 30 IU/ml recombinant human IL-2 (Chiron, Emeryville, CA) for 5 
d in 24-well culture plates. Responder CD8
+
 T cells were then isolated using magnetic bead cell 
sorting (Miltenyi Biotec), then cocultured with CMS4 tumor cells or irrelevant control MethA 
tumor cells (at a T cell-to-tumor cell ratio of 10:1) in 96-well round-bottom plates in a 
humidified incubator at 37°C and 5% CO2 for 48 h. Cell-free supernatants were then stored at 
−80°C until analysis with cytokine-specific ELISA. For evaluation of tumor-specific T cell 
responses within the tumor-draining lymph nodes (TDLNs), these lymphoid organs were 
harvested on day 21 after tumor inoculation, and CD8
+
 MACS T cells were stimulated with 
irradiated (100 Gy) CMS4 cells for 5 d at a T cell-to-tumor cell ratio of 10:1 before being 
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washed with PBS and then restimulated with irradiated CMS4 versus control (MethA; H-2
d
) 
tumor cells at a T cell-to-tumor cell ratio of 10:1 for 48 h. Cell-free supernatants were then stored 
at −80°C until analysis with cytokine-specific ELISA.  
ELISA. In some experiments, control and transduced DCs were stimulated with CD40L
+
 
J558 cells [179] at a 1:1 ratio for 24 h, with supernatants then harvested for determination of 
secreted levels of TNF-α and IL-12p70 using specific ELISAs purchased from BioLegend (San 
Diego, CA) and BD Biosciences, respectively. Supernatants harvested from T cell cultures were 
analyzed for IL-10 and IFN-γ content using specific OptEIA ELISA sets (BD Biosciences) 
according to the manufacturer’s instructions. Triplicate determinations were used in all instances, 
with data reported as the means ± SD.  
Imaging of tumor tissues. Tumor samples were prepared and sectioned as previously 
reported [187]. Briefly, tumor tissues were harvested and fixed in 2% paraformaldehyde (Sigma-
Aldrich) at 4°C for 1 h, then cryoprotected in 30% sucrose for 24 h. Tumor tissues were then 
frozen in liquid nitrogen and 6-mm cryosections prepared. For analysis of T cell subsets, sections 
were first stained with purified rat anti-mouse CD8α or purified rat anti-mouse CD4 mAbs (both 
from BD Pharmingen, San Diego, CA) for 1 h. After washing, sections were stained with Alexa 
Fluor 488-conjugated goat anti-rat secondary Ab (Jackson ImmunoResearch Laboratories, West 
Grove, PA). To detect DCs in tumor tissue, tissue sections were stained with FITC-conjugated 
anti-mouse CD11c Ab (BD Biosciences). For coanalysis of CD4 and Foxp3 expression, sections 
were washed and incubated with FITC-conjugated anti-mouse CD4 Ab and PE-conjugated anti-
mouse Foxp3 Ab (eBioscience, San Diego, CA). For analysis of CD11b+Gr1+ MDSCs, tissue 
sections were incubated with PE-conjugated rat anti-mouse CD11b and FITC-conjugated anti-
mouse Gr1 (both from BD Pharmingen). For analysis of CD31 and NG2 markers, the tissue 
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sections were first incubated with rat anti-mouse CD31 and rabbit anti-mouse NG2 (both from 
Millipore, Bedford, MA) for 1 h at room temperature, then washed with 0.5% BSA and stained 
with Alexa Fluor 488-conjugated goat anti-rat Ab and Cy3-conjugated goat anti-rabbit Ab (both 
from Invitrogen). To determine in situ cell death, an in situ cell death detection kit (Roche 
Diagnostics Systems) was used. After staining with primary and secondary Abs, the slides were 
washed and counterstained with 2 mg/ml Hoechst 33258 (Sigma-Aldrich) for 30 s. After 
washing, sections were then covered in Gelvatol (Monsanto, St. Louis, MO) and a coverslip was 
applied. Slide images were acquired using an Olympus 500 scanning confocal microscope 
(Olympus America, Center Valley, PA). The positively stained cells were quantified by 
analyzing the images at a final magnification of ×20. Cells number and vascular area were 
analyzed using MetaMorph imaging software (Molecular Devices, Sunnyvale, CA).  
MLR and transwell assays. To evaluate the allostimulatory function of control versus 
engineered DCs, MLR were performed as previously described, with minor modification [184]. 
Control C57BL/6 (H-2
b
) DCs (DC.nulls or DC.ψ5 s) or DC.mTbets were seeded (2 × 104 
cells/well) in round-bottom 96-well plates. CD4
+
 MACS (Miltenyi Biotec) splenic T cells from 
wild-type BALB/c (H-2
d) mice were labeled with 0.5 μM CFSE (Sigma-Aldrich) for 15 min at 
room temperature, after which T cells were washed three times with CM, and 2 × 10
5
 cells were 
added to control wells or wells containing DCs in a total volume of 200 μl CM per well. After 72 
h of culture, cells were harvested and analyzed by flow cytometry for dilution of CFSE signal. 
Triplicate determinations were used in all instances, with data reported as the means ± SD.  
Transwell assays were performed as previously reported. Briefly, DC.mTbets or control 
DCs (5 × 10
5
) derived from C57BL/6 mice were plated in the bottom chamber of a 24-well 
transwell plate in 400 μl CM, and, 24 h later, 106 BALB/c splenic T cells (MACS-isolated CD4+ 
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T cells or CD8
+
 T cells) along with 10
5
 H-2
b
 DC.nulls were placed in the upper chamber of the 
transwell plate, bringing the total volume to 600 μl CM. As positive controls, cultures were 
established with C57BL/6 DC.mTbets or control DCs and BALB/c T cells in the upper chamber 
and no cells in the lower chamber. Where indicated, replicate wells received saturating levels of 
neutralizing goat anti–mIL-12p70 pAb or isotype control pAb (both from R&D Systems, 
Minneapolis, MN). Cell supernatants were collected from the upper chamber after 72 h of 
coculture for performance of IFN-γ ELISA. Triplicate determinations were used in all instances, 
with data reported as the means ± SD.  
Statistical analysis. A two-tailed Student t test was used for data analysis. Null 
hypothesis was rejected, and differences were assumed to be significant at a value of p < 0.05.  
3.4 RESULTS 
3.4.1 Phenotypic characterization of DC.mTbets 
Cultured day 7 bone marrow-derived DCs were left uninfected (DC.nulls) or they were infected 
with Ad.mTbet (generating DC.mTbets) or control Ad.ψ5 (yielding DC.ψ5 s) at an MOI of 250 
for 48 h. DCs were then assessed for expression of T-bet protein using immunofluorescence 
microscopy (Fig. 7A), intracellular staining as monitored by flow cytometry (Fig. 7B), and 
Western blotting (Fig. 7C). More than 50% of DC.mTbets expressed elevated levels of T-bet 
protein, which was predominantly localized to the cell nucleus. DC.nulls and DC.ψ5 s expressed 
little or no detectable T-bet protein.  
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Figure 7. Ectopic expression of mT-bet in mouse CD11c
+ 
DCs 
Murine DC.Tbets were generated from bone marrow CD11c
+
 DCs. Bone marrow DCs were cultured in RPMI 1640 
complete medium supplemented with rmGM-CSF and rmIL-4 at 37°C, 5% CO2 for 7 d as previously described 
[188], prior to being transduced with adenovirus containing mT-bet cDNA. A, T-bet protein expression was 
localized to the nucleus in DC.mTbets (MOI of 250) when analyzed by immunofluorescence intracellular staining, 
with little to no expression of T-bet observed in control DCs (DC.nulls and DC.ψ5 s) (original magnification ×120). 
Intracellular staining and flow cytometry (B) and Western blot (C) analyses similarly supported differential 
expression of mT-bet protein in DC.mTbets versus control DCs. In B, inserted numbers in the upper right corner of 
DC.mTbet panels reflect the MOI used for adenoviral infection. Control Ad.ψ5 infections performed at MOI of 500. 
Numbers above gating region reflect the percentage of mT-bet
+
 cells. In C, numbers in parentheses reflect MOI used 
for Ad.mT-bet infection of DCs. DC.ψ5 s were generated using an MOI of 500. All data are representative of 
information obtained in two independent experiments.  
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We next analyzed DC.mTbets versus control DCs for expression of cell surface 
molecules associated with their ability to (co)stimulate T cells (i.e., MHC class I, MHC class II, 
CD40, CD54, CD80, CD86) or to traffick to secondary lymph nodes (i.e., CCR7) to cross-prime 
T cells in vivo. When compared with DC.ψ5 s (thereby controlling for effects associated with 
adenoviral infection) or DC.nulls, we noted no significant differences in expression of any of 
these markers in DC.mTbets. (Data not shown) All DC (>90% CD11c
+
) populations expressed 
an MHC class I
+
, MHC class II
+
, CD40
+
, CD54
+
, CD80
+
, CD86
+
, CCR7
−
 phenotype. 
An analysis of cytokine production by the various DC populations after CD40 ligation 
revealed that DC.mTbets produced slightly more IL-12p70 and TNF-α than did control DCs 
(Fig. 8A). There were no significant differences between the DC cohorts with regard to IL-10 or 
IL-18 production (Fig. 8A), and none of the evaluated DC populations produced detectable 
intracelluar levels of IFN-γ (Fig. 8B). DC.mTbets also failed to secrete discernable levels of 
IFN-γ based on ELISA (data not shown).  
 60 
 
Figure 8. Impact of T-bet gene insertion on DC expression/secretion of cytokines in vitro 
A, DC.Tbets versus control DCs were analyzed by ELISA for secretion of IL-12p70, TNF-α, IL-10, and IL-18 24 h 
after CD40 ligation, as outlined in Materials and Methods. Results were reported as the means ± SD of triplicate 
determinations. *p < 0.05 for DC.mTbets compared with either DC.nulls or DC. ψ5s. B, Expression of intracellular 
IFN-γ was evaluated in DC.mTbets versus control DCs by flow cytometry. All data are representative of three 
independent experiments performed in each instance.  
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3.4.2 DC.mTbets promote superior Type-1 T effector cell induction in vitro without 
differentially affecting T cell proliferation compare to control DCs. 
To determine the impact of transgenic T-bet on the ability of DCs to drive T cell responses in 
vitro, we used MLR. CFSE-labeled CD4
+
 (H-2
d
) T responder cells were cocultured with H-2
b
 
DC.nulls, DC.ψ5s, or DC.mTbets for 3 d, at which time flow cytometry was used to analyze T 
cell proliferation based on dilution of CFSE fluorescence intensity. As shown in Fig. 9A and 9B, 
there was no significant difference between the various DC cohorts in their ability to stimulate 
most allogenic T cells to enter into proliferative cycling. To investigate the potential Type-1-
polarizing effects of DC.mTbets on T cell responders, a Staphylococcus enterotoxin B (SEB) 
model was employed. DC.mTbets or control DCs were pulsed with SEB in vitro for 3 h, then 
washed and cocultured with MACS-purified CD4
+
 or CD8
+
 T cells (from syngenic H-2
b
 
splenocytes) for 72 h. Specific ELISA performed on cell-free supernatants revealed that 
DC.mTbets were superior to control DCs in their capacity to elicit IFN-γ production from 
responder CD4
+
 (Fig. 9C) and CD8
+
 (Fig. 9D) T cells. Hence, consistent with our previous 
findings for human DC.Tbets [175], murine DC.mTbets appear to promote improved Type-1 
immune responsives by contributing differential polarizing, rather than proliferative, signals to 
responder T cells.  
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Figure 9. DC.mTbets promote superior Type-1 T cell responses in vitro, without affecting T cell 
proliferation 
DC.nulls, , DC.ψ5s, and DC.mTbets were generated from C57BL/6 (H-2b) mice and used to stimulate CFSE-
labeled, MACS-purified CD4
+
 T cells isolated from BALB/c (H-2
d
) in MLR cultures as outlined in Materials and 
Methods. After 72 h, T cell proliferation (based on CFSE dilution) was analyzed by flow cytometry (A), with the 
total percentage (mean ± SD) of proliferating T cells reported in B. To assess the differential capacity of DC.mTbets 
to polarize Type-1 T cell responses in vitro, an SEB model was applied. SEB-pulsed DC.mTbets or control DCs 
were cocultured with MACS-purified CD4
+
 (C) or CD8
+
 (D) T cells for 72 h. Cell-free supernatants from these 
cultures were then analyzed using mIFN-γ ELISA. Data are reported as the means ± SD of triplicate determinations. 
All experiments were performed three times, with comparable data obtained in all cases. *p < 0.05 for DC.mTbets 
versus DC.nulls or DC.ψ5s.  
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3.4.3 DC.mTbets promote superior Type-1 T effector cell induction in vitro 
To determine whether DC.mTbets mediate superior Type-1 T cell activation via dominant 
mechanisms involving cell-to-cell contact or secreted mediators, we established transwell MLR 
cultures in which H-2b DCs were either cocultured with responder H-2d CD4
+ 
or CD8
+
 T cells, 
or the two populations were separated from one another. As shown in Fig. 10A and 10B, 
coculture conditions permissive for intimate DC.mTbets and (CD8
+
 or CD4
+
) T cell contact 
yielded increased IFN-γ production from responder T cells when compared with cocultures 
established using DC.nulls or DC.ψ5s. Inclusion of saturating doses of neutralizing anti–IL-
12p70 pAb partially reduced the allostimulatory activity of DC.mTbets (p < 0.05 versus cultures 
supplemented with isotype control pAb). In contrast, when DC.mTbets (lower chamber) were 
separated from T cells cocultured with control DC.nulls (upper chamber), we observed no 
increased production of IFN-γ by responder CD8+ (Fig. 10C) or CD4+ (Fig. 10D) T cells versus 
cocultures established with control DC populations in the lower transwell chamber. As expected, 
in these “separated” (DC.null plus T cell) cocultures, IL-12p70 appeared to play a dominant role 
in the activation of Type-1 alloresponder T cells (Fig. 10
C
, 10D). Therefore, as was the case for 
human DC.hTbets [175], direct DC.mTbet–T cell interaction or close proximity appears crucial 
for the ability of these APCs to promote superior Type-1 T cell activation in vitro via a 
mechanism that is largely IL-12–independent.  
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Figure 10. The optimal Type-1-polarizing capacity of DC.mTbets requires intimate DC–T cell 
contact and is partially dependent on IL-12p70 
Transwell cultures were established using H-2
b
 DCs (i.e., DC.nulls, DC.ψ5s, and DC.mTbets) and H-2d MACS-
isolated, splenic CD8
+
 (A, C) or CD4
+
 (B, D) T cells as outlined in Materials and Methods. T cells were placed in 
the upper transwell chamber, with DCs placed in the upper and lower chambers of the transwell as indicated. After 
72 h of coculture in the absence or presence of 2μg per well of control Ig or neutralizing anti–IL-12p70 pAb, cell-
free supernatant was harvested from the upper well and analyzed using an mIFN-γ–specific ELISA. Data are 
reported as the means ± SD of triplicate determinations. *p < 0.05 versus control DC.nulls or DC.ψ5 s. **p < 0.05 
versus isotype control Ig.  
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3.4.4 DC.mTbets injected i.t. promote protective Type-1 anti-tumor immunity: 
dependence on CD4
+
 T cells, CD8
+
 T cells, and NK cells in vivo 
Based on the reported ability of i.t. injected DC populations to support effective cross-priming of 
therapeutic anti-tumor T cell responses in vivo [41, 67, 184], we next analyzed whether 
DC.mTbets were superior to control DCs in this regard. Mice harboring established (day 7) s.c. 
CMS4 sarcomas were treated i.t. with 1 × 106 DC.mTbets or control DCs, with an identical 
treatment applied 1 wk later (on day 14 posttumor inoculation). As shown in Fig. 11A, therapy 
using DC.mTbets, but not control DCs, resulted in the prolonged suppression of tumor growth (p 
< 0.05 versus control DCs beginning on day 14 posttumor inoculation). DC.mTbet-based therapy 
yielded an approximate 3-wk extension in overall survival versus control therapy (Fig. 11B; p = 
0.0012 versus DC.nulls and p = 0.0014 versus DC.ψ5 s). Repeat experiments in which mice were 
depleted of T cell subsets or NK cells beginning just prior to the application of therapy revealed 
a major dependency of treatment efficacy on both CD4+ and CD8+ T cells (Fig. 11C). A minor 
dependency was also noted for NK cells, as injection of the depleting anti-asialoGM1 Ab 
partially reduced the anti-tumor protection afforded by i.t. administered DC.mTbets (Fig. 11C).  
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Figure 11. I.t. injection of DC.mTbets provides therapeutic benefit that is dependent on CD4
+ 
T cells, 
CD8
+
 T cells, and NK cells 
A, BALB/c mice bearing day 7 s.c. CMS4 tumors were treated with i.t. injection of 1 × 10
6
 DC.mTbets or control 
DCs (DC.nulls or DC.ψ5 s). An identical retreatment was provided 1 wk later. Tumor growth was monitored every 
3–5 d and is reported as means ± SD for five animals per cohort. *p < 0.05 when compared with mice treated with 
DC.nulls or DC.ψ5 s. B, Kaplan-Meier survival plot for the overall survival of mice in the various treatment groups; 
*p = 0.0012 and 0.0014 for DC.mTbet-treated mice versus DC.null- and DC.ψ5 -treated animals, respectively. C, 
The experimental plan in Fig. 11A was modified to include cohorts of CMS4-bearing mice in which CD4
+
 T cells, 
CD8
+
 T cells, or asialoGM1
+
 NK cells were depleted (beginning on day 6 [i.e., 1 d prior to i.t. delivery of 
DC.mTbets]) by specific Ab administration as described in Materials and Methods. *p < 0.05 when compared 
with mice treated with DC.nulls or DC.ψ5 s. Data are representative of three independent experiments performed in 
all cases.  
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3.4.5 I.t. injection of DC.mTbet DCs promotes improved activation of anti-tumor Tc1 
cells in the periphery and increased frequencies of tumor-infiltrating lymphocytes in vivo 
Splenocytes were harvested from CMS4 tumor-bearing animals 7 d after the second i.t. injection 
of DC.mTbets or control therapy (i.e., day 21 post tumor inoculation). After specific MACS 
purification, CD8
+
 T cells were stimulated in vitro with irradiated CMS4 tumor cells and 
analyzed for levels of intracellular IFN-γ as monitored by flow cytometry (6-h assay; Fig. 12A) 
or for secreted levels of IFN-γ by ELISA (24-h assay; Fig. 12B). Whereas splenic CD8+ T cells 
from control-treated mice only rarely produced IFN-γ in response to stimulation with CMS4 
tumor cells, CMS4-reactive Tc1 effector cells were enriched (comprising more than a fourth of 
the splenic CD8
+
 T cell population) in mice treated with DC.mTbets (Fig. 12). Similar analyses 
performed on TDLNs harvested from treated animals suggest increased numbers of both CD4
+
 
and CD8
+
 T cells in the secondary lymphoid organs of DC.mTbet- versus control-treated mice 
(day 21), with CD8
+
 T cells producing enhanced levels of IFN-γ in vitro in response to 
stimulation with CMS4 tumor cells versus control H-2
d
 MethA sarcoma cells (appendix Fig 5).  
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Figure 12. I.t. delivery of DC.mTbets promotes the systemic activation of Type-1 anti-tumor T cells 
Mice bearing day 7 CMS4 tumors were treated as outlined in Fig. 10A. On day 21 posttumor inoculation, 
splenocytes were harvested and CD4
+
 and CD8
+
 T cells were purified by specific MACS. T cells were then 
stimulated in vitro with irradiated CMS4 tumor cells, and levels of intracellular IFN-γ were assessed by flow 
cytometry (A) and secreted levels of IFN-γ were determined by specific ELISA (B). ELISA values are reported as 
the means ± SD of triplicate determinations. *p < 0.05 for DC.mTbets versus DC.nulls or DC.ψ5 s. All data were 
confirmed in three independent experiments.  
The ability of DC.mTbet-based therapy to sponsor robust Type-1 anti-tumor T cell 
responses in the spleen and TDLNs is a minimal criterion for successful immunotherapy. 
Optimal efficacy would be presumed to occur only if such Ag-experienced T cells are recruited 
into the TME where they may regulate tumor growth/progression. As a consequence, we next 
evaluated whether i.t. delivery of DC.mTbets resulted in increased frequencies of tumor-
infiltrating lymphocytes. As shown in Fig. 13, large numbers of CD4
+
 and CD8
+
 T cells were 
readily imaged in day 21 tumor sections generated from DC.mTbet- but not control DC-treated 
mice (Fig. 13). We also observed that the frequency of CD11c
+
 DCs in the TME was very sparse 
in day 21 tumor sections isolated from mice treated with control DCs, but these levels were 
increased >10-fold if the mice had been treated using i.t. delivered DC.mTbets (Fig. 13). This 
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large increase in TIDC appeared to result from two processes: (1) increased longevity of the 
injected DC.mTbets versus control DCs in situ (even though we observed no difference in the 
viability of DC.mTbets versus control DCs at the time of injection), and (2) improved 
recruitment of noninjected host CD11c
+
 DCs into the TME post treatment with DC.mTbets 
versus control therapy (appendix Fig. 6).  
 
 
Figure 13. I.t. delivery of DC.mTbets promotes increased infiltration of T cells and DCs into the 
TME 
BALB/c mice bearing day 7 CMS4 tumors were treated as described in Fig. 11A. On day 21, tumors were resected, 
fixed, frozen, and sectioned. Tissue sections were then stained with anti-CD4, anti-CD8, or anti-CD11c mAb, 
counterstained with Hoescht (nuclear) dye, and then analyzed by fluorescence microscopy as described in Materials 
and Methods (A) (original magnification ×20). We also report the means ± SD values for the number of tumor-
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infiltrating CD4
+
 T cells (B), CD8
+
 T cells (C), and CD11c
+
 cells (D) based on the imaging of 10 high-powered 
fields per slide. **p < 0.01 for DC.mTbets versus DC.nulls or , DC.ψ5s. Three independent experiments were 
performed, with each yielding comparable data. HPF, high-powered field.  
 
3.4.6 DC.mTbets-based therapy normalizes the TME: effects on MDSCs, regulatory T 
cells, and angiogenesis 
CD11b
+
Gr1
+
 MDSCs are both necessary and sufficient to mediate the suppression of T and B 
cell responses in the TME [189]. To determine whether i.t. delivery of DC.mTbets alters the 
prevalence of MDSCs in the TME, tumor sections were costained with anti-CD11b and anti-Gr1 
mAb and analyzed by fluorescence microscopy. As shown in Fig. 8, treatment with DC.mTbets, 
but not control DCs, resulted in a significant decrease in the numbers of Gr1
+
CD11b
+
 MDSCs in 
the day 21 CMS4 TME. Similarly, CD4
+
CD25
+
 Tregs are commonly enriched in the periphery 
and, even more so, in the TME of patients with cancer [187, 190, 191] where they may 
compromise anti-tumor T effector cells [190, 192, 193]. As shown in Fig. 14, the prevalence of 
CD4
+
Foxp3
+
 TILs was significantly decreased as a consequence of DC.mTbet delivery into the 
TME. Additionally, based on substantive treatment effects on CD8
+
 TIL numbers, the ratio of 
CD8
+
 T cells to Tregs in the TME of mice treated with DC.mTbets versus control DCs was 
dramatically increased (data not shown).  
Effective immunotherapy has also been posited to result in vascular normalization, a 
phenomenon in which leaky microvessels in the TME are eradicated [194]. This results in larger 
(diameter), more stable blood vessels in association with decreased interstitial fluid pressure, and 
the improved deliverability of pharmacologic agents and/or immune effector cells into the TME, 
 71 
leading to corollary increases in tumor cell apoptosis [195]. Given the profound increases in 
TILs observed after treatment with DC.mTbets, we next analyzed the surface area and 
morphologic complexity of CD31
+
 vascular structures in the TME of treated mice. As shown in 
Fig. 14, NG2
+
 pericyte-decorated CD31
+
 vessels were dramatically reduced in their complexity 
(based on morphology and quantitated by calculating total CD31
+
 cell surface area) in tumors 
treated with DC.mTbets versus control DCs. Indeed, as a consequence of DC.mTbet-based 
therapy, the weblike network of branched microvessels was eradicated, leaving behind simple 
vascular tube structures.  
 
 
Figure 14. I.t. delivery of DC.mTbet reduces MDSC and Treg numbers, normalizes blood vessels, 
and enhances tumor cell apoptosis in the TME 
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A, Day 21 tumor sections prepared as described in the Fig. 13 legend and Materials and Methods were analyzed by 
fluorescence micrscopy to detect CD11b
+
Gr1
+
 MDSCs, CD4
+
Foxp3
+
 Tregs, CD31
+
NG2
+
 blood vessels, and 
apoptotic cells (by TUNEL) (original magnification ×20). In all cases, sections were counterstained with Hoechst 
dye to detect nuclei. The mean ± SD number of each parameter is reported based on the imaging of 10 high-powered 
fields per slide in B. **p < 0.01 for DC.mTbets versus DC.nulls or DC.ψ5 s. Three independent experiments were 
performed, with each yielding comparable data. HPF, high-powered field.  
 
3.4.7 DC.mTbets-based therapy results in increased apoptosis in the TME 
A corollary expectation for improved recruitment of Tc1 TIL effector cells and for the anti-
angiogenic effects associated with i.t. delivery of DC.mTbets would be increased (tumor) 
cellular apoptosis in the TME of this treatment cohort. As shown in Fig. 14, the number of 
TUNEL
+
 events within the CMS4 TME was increased by >10-fold after two treatment cycles 
with DC.mTbets versus control DCs. 
3.5 DISCUSSION 
Although T-bet is commonly considered as a master regulator of the Type-1 T cell responses [50, 
196, 197], it also clearly plays a permissive role in supporting proinflammatory responses from 
cells of the innate immune system [198, 199]. Indeed, the capacity of DCs to promote Type-1 
immunity has been reported to be highly dependent on the low levels of T-bet protein 
constitutively expressed by at least some subsets of DCs [50]. Hence, we hypothesized that the 
reinforcement of T-bet expression in DCs using rAd.mT-bet viral transfection would yield robust 
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DC1-type APCs that were competent to (re)polarize Type-1 anti-tumor T cell responses in vitro 
and in vivo.  
The major findings in the present study are that DCs engineered to express the T cell 
transactivator T-bet serve as an effective therapeutic agent (compared with control DCs) when 
delivered into the TME, based on improved (1) cross-priming of systemic anti-tumor Type-1 T 
cell responses, (2) frequencies of Type-1 TILs and CD11c
+
 DCs in the TME, (3) normalization 
of the TME (based on reductions in MDSC frequencies and vascular complexity), and (4) 
frequencies of apoptotic (TUNEL
+
) tumor cells in TME. Ab depletion studies support the 
required action of both CD4
+
 and CD8
+
 T cells (in addition to asialoGM1
+
 NK cells) in the 
treatment effectiveness of DC.mTbets. Notably, CD8
+
 T cells isolated from the spleens and 
TDLNs of DC.mTbet-treated mice directly recognized (based on IFN-γ production) MHC class 
I
+
, MHC class II
−
 CMS4 tumor cells in vitro. These effector cells are likely activated in vivo as a 
consequence of APCs that have acquired apoptotic/necrotic tumor debris and then emigrated 
from the therapy-normalized TME to the TDLNs and spleen. The therapy-induced tumoricidal 
process within the TME does not appear to involve the differential, direct tumoricidal activity of 
injected DC.mTbets, as these APCs exhibited only low, control-level capacity to promote the 
apoptotic death of CMS4 tumor cells in vitro (Data not shown). 
Interestingly, i.t. delivery of DC.mTbets significantly reduced levels of Tregs (based on a 
CD4
+
Foxp3
+
 phenotype) in the TME when compared with control treatment groups. 
Furthermore, the anti-tumor effects associated with this approach appear due to the 
“overrunning” of a limited Treg suppression pathway via the influx of large numbers of therapy-
induced, Type-1 effector T cells into the TME. This reversal in CD8
+
 T cell versus Treg 
numbers/function within the TME may be facilitated or sustained due to therapy-associated 
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changes in CD11b
+
Gr1
+
 MDSC content (reduced by ∼60–70% in the TME). MDSCs have been 
reported to inhibit T effector cell function via a range of mechanisms, including the depletion of 
amino acids [arginine, tryptophan, or cystein/cystine [200, 201]], the production of ROS and 
peroxynitrite [202] and the uncoupling of TCR-ζ–chain signaling [203], among others. How 
DC.mTbet therapy limits MDSC numbers in the tumor remains unknown, but given the 
suggested normalization in vascular structures in the TME postinjection of DC.mTbets, one 
could consider that reductions may occur in hypoxia-sensitive chemokines (such as CCL2 and 
CCL5) that are known to recruit MDSCs [204, 205]. Alternatively, or additionally, early Type-1 
T cell recruits into the TME may limit the development of MDSCs from precursor myeloid cells 
[206]. Regardless of such potential mechanisms, one could consider inhibition of residual MDSC 
numbers/function in the TME (using drugs such as sunitinib) as a means to further improve the 
efficacy of i.t. delivered DC.mTbets in combinational treatment.  
The present findings confirm and extend our previous human in vitro studies [175], 
where DC.hTbets were found to promote the differentiation of Type-1 T effector cells without 
significantly altering responder T cell proliferation. As with human DC.Tbets [175], we observed 
that DC.mTbets were minimally altered with regard to their cell-surface expression of MHC, 
costimulatory, or integrin molecules. A slight point of variance with human DC.Tbets that failed 
to produce increased quantities of cytokines upon activation [175], murine DC.Tbets (versus 
control DCs) secreted higher levels of IL-12p70 and TNF-α (but not IL-10, IL-18, or IFN-γ) after 
CD40 ligation in vitro. Human DC.Tbets were determined to mediate their Type-1-polarizing 
effects on T cells in a largely contact-dependent manner, which did not appear to involve key 
cytokines such as IL-12p70 or IFN-γ itself [175]. In the present study, we have also observed 
that the superior ability of DC.mTbets to activate Type-1 CD4
+
 and CD8
+
 T cell responses in 
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vivo requires intimacy between APCs and T cells. However, unlike the human model, murine 
DC.mTbets elaborated IL-12p70 appears to play at least a minor role in the resultant 
development of Tc1 and Th1 responses. The in vivo relevance of DC-secreted products in the 
therapeutic mechanism of action associated with DC.mTbets will be best determined in models 
using DCs prepared from specific cyotokine-deficient strains of animals. Given the breadth of 
available knockout strains (including IL-12p35
−/−
 and IL-12p40
−/−
 mice) on the H-2
b
 (but not H-
2
d
) background, we are presently developing a MCA205 sarcoma model in syngenic C57BL/6 
mice to resolve how specific cytokine production competency by DC.Tbets relates to the 
therapeutic efficacy of this biologic agent. Should the in vivo role of IL-12p70 be shown to be 
minimal in the setting of DC.mTbet-based therapeutic efficacy, it would then be intriguing to 
evaluate the impact of combined T-bet plus IL-12p70 gene therapy, given the potentially 
synergistic/complementary mechanisms of action associated with these agents in sponsoring 
protective, Type-1 anti-tumor immunity.  
In summary, our results suggest that genetic engineering of DCs to express the Th1 
transcription factor T-bet yields an APC that is competent to cross-prime protective Type-1 anti-
tumor immunity after delivery into the TME in vivo. DC.Tbets also appear to mediate a range of 
locoregional effects (i.e., MDSC reduction, vascular normalization) that may improve the 
delivery/function of therapy-induced T effector cells into/within the TME. Despite potential 
minor differences between human and mouse DC.Tbets with regard to secretion of IL-12p70 and 
TNF-α (and possibly additional cytokines) and the role played by IL-12p70 in supporting the 
Type-1-polarizing activity of DC.Tbets, we think that our preclinical studies advocate the 
implementation of DC.Tbets as a therapeutic agent in the management of patients with cancer.  
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4.1 ABSTRACT 
Murine dendritic cells (DC) transduced to express the Type-1 transactivator T-bet (i.e. 
mDC.Tbet) and delivered intratumorally (i.t.) are superior to control wild-type DC in slowing  
the  growth  of  established  subcutaneous  (s.c.)  MCA205  sarcomas  in  vivo. Protective 
immunity required the participation of both NK cells and CD8
+
 T cells, whose induction was 
independent of the ability of injected mDC.Tbet to produce IL-12 family member cytokines or 
IFN-γ, or to migrate to tumor-draining lymph nodes (TDLN) based on CCR7 ligand chemokine 
recruitment. However, optimal therapeutic protection afforded by i.t. delivered mDC.Tbet did 
require that the injected DC to express MHC class I molecules and was associated with the acute 
recruitment of (naïve) T cells and NK cells into the treated TME. Conditional (CD11c-DTR) or 
genetic (BATF3
-/-
) deficiency in host antigen crosspresenting DC did not diminish the 
therapeutic action of i.t.-delivered wild-type mDC.Tbet. When taken together, our data suggest 
that protective anti-tumor CD8
+
 T cell priming resulting from mDC.Tbet gene therapy 
predominantly occurs extranodally within the tumor site. Consistent with such a paradigm, we 
observed that mDC.Tbet (versus control mDC.Null) intrinsically produce elevated levels of the 
chemokines and promoted the acute infiltration of NK cells and naïve CD45RB
+
  T cells into the 
TME. 
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4.2 INTRODUCTION 
Dendritic cells (DC) are key antigen-presenting cells (APC) that serve as qualitative and 
quantitative rheostats for developing T cell responses in immune competent hosts [207-209]. By   
carefully  manipulating  the  conditions  under  which  DC  acquire,  process  and cross-present   
antigens,  the  resulting  cognate  T  cell-mediated  immunity  may  be modulated with regard to 
its magnitude, functional polarity and effector/memory status [210, 211]. When taken in the 
context of intrinsic or therapeutically-induced immunity, DC can profoundly  impact  T  cell-
mediated  protection  versus  pathogenesis  in  the  setting  of infectious disease, autoimmunity or 
cancer [209, 212]. In the cancer setting, Type-1 CD8+  T cell (aka Tc1) responses have been 
most commonly associated with endogenous host protection  or  therapeutic  benefit  to  
immunotherapy  [213-216].  The ability to generate Type-1-polarized immunity has in turn been 
shown to depend on intrinsic expression of the transactivator protein T-bet (aka TBX21) by T 
cell responders, but also perhaps more intriguingly, by DC [217]. 
We have recently reported that DC transduced to express high levels of ectopic T-bet 
(DC.Tbet) are superior activators of Type-1 CD8+  T cells from naïve T cell precursors in 
human in vitro experiments [218], and that when injected directly into established CMS4 
sarcoma lesions in Balb/c (H-2d) mice, that protective immunity results [219] . It remains 
unclear as to how DC.Tbet promote superior protective immunity, particularly in vivo. Using 
a s.c. MCA205 sarcoma model in C57BL/6 recipients and a range of informative syngenic (H-
2b) mutant strains of mice serving as sources of mDC.Tbet cell for injection or as model hosts, 
we observed that i.t.  delivery of  mDC.Tbet  promotes  the rapid recruitment  and  
(cross)priming  of  polarized  Type-1  NK  and  CD8+     T  cell-mediated immunity within the 
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TME that protects against tumor  progression. These events were associated with a differential 
chemokine profile produced by injected DC.Tbet versus control DC, with the subsequent Type-
1 polarization of CD8+ T effector cells proving to be independent of mDC.Tbet production of IL-
12 family member cytokines or IFN-γ. Overall, our data support a model in which the injected 
mDC.Tbet serve as dominant drivers for the extranodal (cross)priming of therapeutic immunity 
within the TME. 
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4.3 MATERIALS AND METHODS 
Mice. Female 6-8 week old wild-type C57BL/6 (H-2b) mice, as well as, IL-12p35
-/-
, IL-12p40
-/-
, 
IFN-γ-/-, β2M-/- and CCR7-/- mice (all on the B6 background) were purchased from the Jackson 
Laboratory (Bar Harbor, ME). Female CD11c-DTR (H-2b) conditional DC-deficient mice were 
kindly provided by Dr. Adrian Morelli (University of Pittsburgh). Female BATF3
-/- 
mice 
deficient in cross-presenting DC were generated from 129-Batf3
-/-
 mice kindly provided   by   
Dr.  Ken Murphy (Washington University-St.  Louis)  after backcrossing with C57BL/6 mice for 
5 generations. Tbet-ZsGreen reporter mice were kindly provided under an MTA by Dr. Jinfang 
Zhu (NIH/NIAID) via the NIAID repository maintained at Taconic (Hudson, NY). All animals 
were handled under aseptic conditions according to Institutional Animal  Care  and  Use   
Committee-approved  protocol  and  in accordance with recommendations for the proper care 
and use of laboratory animals. 
Cell lines and culture. The MCA205 sarcoma (H-2b) cell line was purchased from the 
American Type Culture Collection (ATCC; Manassas, VA), was free of  Mycoplasma 
contamination  and  was  maintained  in  complete  medium  (CM:  RPMI-1640  media 
supplemented with 10% heat-inactivated fetal bovine serum, 100 μg/mL streptomycin,100 
U/mL penicillin, and 10 mmol/L L-glutamine, all reagents were purchased from Invitrogen, 
Carlsbad, CA) at 5% CO2  tension in a 37°C humidified incubator. 
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Generation of BM-derived DC and transduction with adenoviral vectors in vitro. DC 
were generated from the tibias/femurs of mice, and infected with recombinant adenovirus (either  
empty, control Ad.ψ5 or Ad.mT-bet) at an MOI of 250 for 48h, as previously described  
[ 2 1 9 ] .   Intracellular staining and flow cytometry  was  used  to  document expression of 
mTbet in Ad-infected DC (mDC.Tbet) as previously reported (14) 
Therapy model. Recipient wild-type, mutant or transgenic (H-2b) mice received s.c. 
injections of 5 x 105   MCA205 sarcoma cells in the right flank on day 0. On day 7 or 8 post-
tumor inoculation, mice were randomized into treatment cohorts of 5 mice each exhibiting 
comparable mean tumor sizes (i.e. approximately 40 mm2).  Control DC (mDC.Null) or 
mDC.Tbet (106) developed from wild-type C57BL/6 or syngenic mutant mice were then 
injected i.t. in a total volume of 50 µl (in PBS) on days 7-8 post-tumor inoculation and again 
1 week later. Mean tumor size (+ SD) was then assessed every 3 or 4 days and recorded in 
mm2   by determining the product of the largest orthogonal diameters measured by vernier 
calipers. Mice were sacrificed when tumors became ulcerated or if they reached a size of 400 
mm2, in accordance with IACUC guidelines. 
In vivo depletion of CD8+ T cells, NK cells and CD11c+ DC. In selected experiments 
where indicated, mice were injected i.p. with 100 µg anti-CD8 mAb3-6.7 (ATCC) or 50 µl anti-
asialoGM1 pAb (anti-asGM1; WAKO, Osaka, Japan) on days 6, 13 and 20 after tumor 
inoculation. In some experiments, anti-asGM1 antibody was administered on days 13 and 20 
post-tumor inoculation.  To deplete CD11c+
  
DC  from  CD11c-DTR  mice, diphtheria toxin 
(DT; Sigma-Aldrich, St. Louis, MO) was provided i.p. at a dose of 4 µg DT/kg beginning on 
day 6 post-tumor inoculation, as previously described [220]. Specific cell depletion was > 95% 
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effective in vivo based on flow cytometry analysis of peripheral blood monuclear cells obtained 
by tail venipuncture from treated mice 24-48h after Ab or DT administration (data not shown). 
Evaluation of CD8+ T-cell responses against MCA205 tumor cells ex vivo. For in 
vitro stimulation cultures, spleens were harvested from 2 mice per cohort at various 
indicated timepoints after the intratumoral injection of PBS, mDC.Null or mDC.Tbet, and 
pooled splenocytes stimulated with irradiated (100 Gy) MCA205 cells (2 x 105 cells/well) in the 
presence of 30 IU/ml recombinant human IL-2 (Chiron Corp., Emeryville, CA) for 5 days in 24 
well culture plates. Responder CD8+ T cells were then isolated using magnetic bead cell sorting 
(Miltenyi Biotec, Auburn, CA), then cocultured with MCA205 tumor cells or irrelevant control 
tumor cells (T cells: tumor cells = 10:1) in 96-well round bottom plates in a humidified incubator 
at 37°C and 5% CO2 for 48h. Cell-free supernatants were stored at -80
oC prior to analysis using 
cytokine-specific OptEIA ELISA sets (BD Biosciences, San Diego, CA) according to the 
manufacturer’s instructions. Triplicate determinations were used in all instances, with data 
reported as the mean + SD. 
Imaging of tumor tissues. Tumor samples were prepared and sectioned as previously 
reported [219] . Briefly, tumor tissues were harvested and fixed in 2% paraformaldehyde 
(Sigma-Aldrich) at 4°C for 1h, then cryoprotected in 30% sucrose for 24 hours. Tumor tissues 
were then frozen in liquid nitrogen and 6 micron cryosections prepared. For analysis of T cell 
subsets, sections were first stained with purified rat anti-mouse CD8α or purified rat anti-mouse 
CD4 (both from BD-Pharmingen, San Diego, CA) mAbs for 1h. After  washing,  sections  
were  stained  with  PE-conjugated  goat  anti-rat  secondary antibody (Jackson 
ImmunoResearch, West  Grove,  PA). To detect NK cells and naïve leukocytes, tissue sections 
were first stained with  goat anti-mouse NKp46 antibody, followed by Cy3-conjugated donkey 
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anti-goat pAb (both from Invitrogen). To detect naïve leukocytes, tissue sections were stained 
with Cy5-conjugated rat anti-mouse CD45RB antibody (Abcam, Cambrideg, MA). Cell nuclei 
were then stained with DAPI as previously described [ 219] . After washing, sections were then 
covered in Gelvatol (Monsanto, St. Louis, MO) and a coverslip applied. Slide images were 
acquired using an Olympus 500 scanning confocal microscope (Olympus America). The 
positively stained cells were quantified by analyzing the images at a final magnification of ×20. 
The number of cells in sections with a given fluorescence phenotype was quantitated using 
Metamorph Imaging software (Molecular Devices, Sunnyvale, CA). 
RNA purification and RT-PCR array. Total RNA was isolated from mDC.Tbet and 
mDC.Null using Trizol reagents (Invitrogen). Total RNA was further purified using the 
RNeasy Plus Mini Kit (Qiagen) including the gDNA Eliminator spin column. The purity and 
quantity of the total RNA was assessed using Nanodrop ND-1000 (CelBio SpA, Milan, Italy). 
Total RNA (1 µg) was reversed transcribed into cDNA using the RT2 First Strand Kit (Qiagen) 
and the cDNA added to RT2 SYBR Green ROX™ qPCR Mastermix (Qiagen) and used for 
quantitative PCR using  the RT2 Profiler PCR Array (96-well) for Mouse Chemokines and 
Receptors (Qiagen) all  according to the manufacturer’s instructions. Reactions were performed 
on a StepOnePlusTM Real-Time PCR thermocycler (Applied Biosystems) using the 
recommended cycling conditions.  All mRNA expression levels were normalized to the 
expression of GAPDH mRNA 
Statistical analysis.  Comparisons between groups were performed  using  a  two-tailed 
Student's t test or one-way Analysis of Variance (ANOVA) with post-hoc analysis, as indicated. 
All  data  were  analyzed  using  SigmaStat  software,  version  3.5  (Systat  Software,  USA). 
Differences with a p-value < 0.05 were considered as significant. 
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4.4 RESULTS 
4.4.1 Therapeutic benefits of intratumoral delivery of mDC.Tbet are both T and NK cell-
dependent 
To assess the requirement for both innate and adaptive immunity in a successful therapeutic 
response to i.t. mDC.Tbet-based treatment (provided on days 7 and 14 post-tumor s.c. MCA205 
sarcoma inoculation), we employed wild-type C57BL/6 or syngenic RAG1
-/-
 mice as hosts, 
without or with co-treatment of anti-asialoGM1 pAb or anti-CD8 mAb to depleted NK cells and 
CD8
+
 T cells, respectively. We observed that intratumoral delivery of mDC.Tbet, but not control 
mDC.Null slowed MCA205 tumor growth in wild-type C57BL/6 mice (Fig. 15A) but not B and 
T cell-deficient RAG1
-/-
 mice (Fig. 15B).  Selective depletion of either CD8
+
   T cells or NK 
cells (beginning on day 6 post-tumor inoculation) also completely ablated protection against 
tumor growth afforded by intratumoral delivery of mDC.Tbet (Fig. 15C, 15D). Interestingly, 
even late depletion of NK cells (beginning on day 13 post-tumor inoculation) resulted in a 
blunting of anti-tumor protection suggesting the continued importance of NK function in the 
“booster” phase of mDC-Tbet-based i.t. therapy (Fig. 15D). 
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Figure 15. Intratumoral delivery of mDC.Tbet into established subcutaneous MCA205 sarcoma 
slows tumor growth via a mechanism involving innate and adaptive immunity 
Control DC (mDC.Null) or mDC.Tbet were generated from the bone marrow of wild-type C57BL/6 mice as 
outlined in Materials and methods. Phosphate-buffered saline or 10
6
 mDC (as indicated) were then injected directly 
into subcutaneous MCA205 sarcomas established in syngenic wild-type (A) or RAG1
−/−
 (B) mice on days 7 and 14 
after tumor inoculation. The experiment described in a was then repeated, with cohorts of mDC.Tbet-treated mice 
also receiving intraperitoneal injections of depleting anti-CD8 (C) or anti-NK (i.e. anti-asGM1 on days 6, 13 and 20; 
or on days13 and 20; D) antibodies. In all cases, tumor growth was monitored every 3–4 days and is reported in mm2 
(mean±s.d. of five animals per group). Data are representative of three independent experiments performed. *P<0.05 
versus phosphate-buffered saline or mDC.Null on the indicated days of analysis (ANOVA). 
 
A B 
C D 
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4.4.2 Intratumoral delivery of T-bet gene transduced DC (DC.mTbet) generated from 
wild-type  or  IL-12p35
-/-
,  IL-12p40
-/- 
  or  IFN-γ-/-   mice  provide  similar  therapeutic 
benefit  against  MCA205  sarcomas 
 We have previously reported that human DC engineered to express ectopic Tbet (i.e. hDC.Tbet)  
promote superior Type-1 T cell polarization in vitro via a mechanism that is poorly antagonized 
by neutralizing anti-IL12 or anti-IFN-γ  antibodies [218]. However, in contrast to hDC.Tbet that 
are poor cytokine (including  IL-12p70  and  IFN-γ)  secretors  when  compared  with  their  
untransfected counterparts [218], mDC.Tbet actually produce significantly more IL-12p70 than 
control DC [219] which could underlie their improved therapeutic potency in tumor-bearing 
mice. To definitively address the role of intrinsic IL-12p70 and IFN-γ production from 
mDC.Tbet in their therapeutic efficacy, we generated control DC (DC.Null) and DC.Tbet from 
the bone marrow of wild-type C57BL/6 mice or IL-12p35
-/-
, IL-12p40
-/- 
or IFN-γ-/- mice (on a 
C57BL/6 background), and injected these cells directly into s.c. MCA205 sarcomas that had 
been established for 7 days in C57BL/6 mice. An identical treatment was provided again one 
week later (i.e.  On day 14 post-tumor injection).  As shown in Fig. 16, untreated MCA205-
bearing mice or tumor-bearing mice treated with control DC (regardless of their source) 
displayed indistinguishable progressive tumor growth.  In contrast, therapies integrating i.t. 
delivery of wild-type DC.Tbet or DC.Tbet developed from wild-type C57BL/6 mice or IL-
12p35
-/-
, IL-12p40
-/-
 (Fig. 16A), or IFN-γ-/- (Fig.  16B) mice resulted in similarly prolonged 
suppression of tumor growth. These data suggest that (optimal) therapeutic efficacy of this 
approach is not dependent upon intrinsic production of IL-12 family member cytokines (i.e. IL-
12p70, IL-23 or IL-35; ref. 16) or IFN-γ by mDC.Tbet. 
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Figure 16. Delivery of mDC.Tbet into tumors mediates antitumor activity independent of the 
intrinsic capacity of the injected DCs to produce IL-12 family member cytokines or IFN-γ 
Control mDC.Null or mDC.Tbet were generated from the bone marrow of C57BL/6 wild-type (WT) mice or from 
syngenic IL-12p35
−/−
 (p35
−/−
) or IL-12p40
−/−
 (p40
−/−
) mice (A) or IFN-γ−/− (IFN−/−) mice (B). The various DC (106) 
were then injected directly into subcutaneous MCA205 sarcomas established in wild-type C57BL/6 mice on days 7 
and 14 after tumor inoculation. Tumor growth was then monitored every 3–4 days and is reported in mm2 
(mean±s.d. of five animals per group). Data are representative of three independent experiments performed in each 
case. *P<0.05 for mDC.Tbet (WT), mDC.Tbet (p35
−/−
), mDC.Tbet (p40
−/−
) and mDC.Tbet (IFN
−/−
) versus control 
mDC.Null-treated animals on the indicated days of analysis (ANOVA). 
4.4.3 Intratumoral delivery of DC.Tbet generated from β2M-/-  mice provides an initial 
wild-type level of therapeutic protection that later becomes sub-optimal, which correlates 
with anti-tumor CD8
+
  T cell responsiveness in treated mice 
Our previous work suggested that the improved ability of DC.Tbet to elicit protective Type-1 
CD8+ T cell responses required the intimate contact or close proximity of these two cell 
A B 
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populations during the antigen crosspresentation process [218, 219]. To investigate the 
requirement of MHC  class  I/peptide-presentation  by  injected  mDC.Tbet  in  the  therapeutic  
benefits associated with this cellular therapy, we delivered control or mDC.Tbet generated 
from wild-type versus  β2M-/- mice into s.c. MCA205 tumors on days 7 and 14 post-tumor 
inoculation and analyzed tumor growth and anti-tumor CD8+ T cell function over time. We 
observed that treatment with mDC.Tbet developed from β2M-/- (i.e. mDC.Tbet (β2M-/-)) or 
wild-type C57BL/6 (i.e. mDC.Tbet (WT)) mice provided a comparable degree of protection 
against tumor growth through day 16-19 post-tumor inoculation, at which time tumors in the 
mDC.Tbet (β2M-/-)-treated cohort re-established accelerated growth kinetics versus tumors in 
mice treated with mDC.Tbet (WT) cells (Fig. 17A). An analysis of splenic CD8+ T cells 
harvested from the treated animals on day 18 and 34 revealed that although T cell production of 
IFN-γ in response to in vitro stimulation with MCA205 tumor cells was elevated to a 
comparable degree in the mDC.Tbet (WT) and mDC.Tbet (β2M-/- )-treated cohorts on day  18, 
only the mice receiving mDC.Tbet (WT) cells exhibited boosted anti-tumor  Tc1  responses  
on  day  34  of  the  study  (Fig.  17B). Indeed, anti-MCA205 responses among CD8+ T cells 
harvested from mice treated with mDC.Tbet (β2M-/-) had dramatically eroded to essentially 
control levels by day 34. These data tentatively suggest that MHC class I expression by the 
injected mDC.Tbet may not be required for the initial induction of anti-tumor CD8+ T cells 
(despite its expected requirement for direct crosspresentation of antigen to T cells by injected 
DC; ref. [229], but that it is likely needed for the sustained function and therapeutic action of T 
effector cells in treated mice on or after day 16 of treatment. 
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To  test  this  directly,  we  performed  a  “criss-cross”  study  design  in  which  
MCA205 tumor-bearing mice first received i.t. delivery of mDC.Tbet (WT) or mDC.Tbet (β2M-
/-) on day 7 post-tumor inoculation, followed by either population of mDC.Tbet cells one week 
later. Control therapy consisted of i.t. delivered DC.Null on both days 7 and 14. As 
depicted in Fig. 17C, all therapies using mDC.Tbet (from either WT or β2M-/- mice) exhibited 
indistinguishable anti-tumor protection benefits through day 17 post-MCA205 inoculation. 
Thereafter, the extended therapeutic efficacy was greatest in mice receiving 2 injections of 
mDC.Tbet (WT), followed by mice receiving mDC.Tbet (WT) on day 7 followed by mDC.Tbet 
(β2M-/-), followed by mice receiving mDC.Tbet (β2M-/-) on day 7 regardless of which 
secondary treatment was applied. These results suggest that durability of protective immunity (> 
day 17) activated by mDC.Tbet-based treatment is determined by whether the injected mDC.Tbet 
express MHC class I at the time of priming (with the most robust responses involving day 7 
delivery mDC.Tbet (WT) cells).  Therapies initiated with mDC.Tbet (β2M-/-) cells atrophy over 
time and are not “salvaged” by secondary treatment with   DC.Tbet (WT) cells.  Furthermore, 
therapy initiated with DC.Tbet (WT) cells deteriorates more quickly if DC.Tbet (β2M-/-) cells 
rather than DC.Tbet (WT) cells are delivered on day 14 post-inoculation.  
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Figure 17. Intratumoral therapy with DC.Tbet developed from β2M−/− mice promotes a transient 
phase of antitumor benefit that ultimately fails, leading to the re-establishment of progressive tumor growth 
which cannot be ‘rescued’ by booster injections of mDC.Tbet 
A. Control mDC.Null or mDC.Tbet were generated from the bone marrow of wild-type C57BL/6 mice (WT) or 
syngenic (H-2
b
) mice deficient in MHC class I expression (based on β2m-deficiency; β2M
−/−
) as outlined in 
Materials and methods, and (10
6
) of a given APC population injected directly into established subcutaneous 
MCA205 sarcomas in C57BL/6 mice on days 7 and 14 after tumor inoculation. Tumor growth was then monitored 
every 3–4 days and the tumor size reported in mm2 (mean±s.d. of five animals per group). In B, on day 18 or 34 
after tumor inoculation (i.e. 4 or 20 days after the second DC injection, respectively), CD8
+
 splenocytes were 
(MACS) isolated for functional analysis. CD8
+
 T cells were cocultured in the absence or presence of irradiated 
MCA205 tumor cells at a 10:1 (T cell-to-tumor cell ratio) for 48 h, at which time cell-free supernatants were 
analyzed for IFN-γ content by ELISA. Reported data have deducted values obtained for T-cell-only cultures. 
*P<0.05 (t-test) versus mDC.Null (WT); **P<0.05 versus all other cohorts (ANOVA). In c, a study design was 
repeated, with the exception that the second intratumoral injection of mDC.Tbet (day 14 after tumor inoculation) 
A 
B 
C 
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was either mDC.Tbet (WT) or mDC.Tbet (β2M−/−). Data are representative of three independent experiments 
performed. *P<0.05 versus mDC.Null (WT) (t-test); **P<0.05 versus the DC.Tbet (WT)→DC.Tbet (WT) treated 
cohort (ANOVA). Panel data are representative of three independent experiments performed. 
 
4.4.4 Therapeutic benefits provided by intratumoral delivery of mDC.Tbet is independent 
of host CD11c+  and CD103+CD11b- DC populations and does not require mDC.Tbet 
trafficking to  secondary lymphoid tissue 
Our therapeutic results using mDC.Tbet (β2M-/-) suggested the enhanced early priming of anti-
MCA205 CD8
+
  T cells in a system where the injected APC were conceptualy not competent in 
crosspriming capacity. This suggested a possible paradigm in which the injected mDC.Tbet 
might directly or indirectly (via NK cell cross-licensing) [221, 222] activate host DC populations 
known to effectively crossprime T cells, such as CD8α+CD11c+ DC or CD103+CD11bneg DC 
[223-225], in the TME or tumor-draining lymph node. To address this issue, mDC.Tbet were 
injected into s.c.  MCA205 tumors established in BATF3
-/-
 mice (deficient in CD8α+CD11c+ and 
CD103
+
CD11b
neg
 DC; ref. [224] ) as a therapy on days 7 and 14 post-tumor inoculation. In both 
instances, mDC.Tbet-based treatment provided substantial and sustained anti-tumor protection 
(Fig. 18A) suggesting that these important host cross-priming DC populations are not critically 
required in this process.  Since  additional  host  CD11c
+
CD8αnegDC populations might also 
participate in the therapeutic crosspriming of adaptive immunity in our  model,  we  also  
delivered  mDC.Tbet  (WT)  into  MCA205  tumors  established  in CD11c-DTR mice to which 
DT could then be administered in order to selectively deplete CD11c
+ 
 host DC in vivo. As 
shown in Fig. 18B, we observed that this maneuver had no detrimental impact on the protection 
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of tumor-bearing mice treated with mDC.Tbet (WT), suggesting that host CD11c+  DC did not 
play a dominant role in the anti-tumor benefits associated with this immunotherapy. 
Expression of CCR7 by crosspresenting DC is required for their migration from 
peripheral tissue sites to secondary lymphoid organs in response to ligand chemokines, CCL19 
and CCL21 [226-229].  To address the requirement of i.t.-delivered mDC.Tbet to migrate to 
tumor-draining lymph nodes in order to crossprime therapeutic T cells that provide protection 
against tumor progression, we generated these APC from wild-type or CCR7
-/-
 mice and injected 
them into MCA205 sarcomas established in wild-type C57BL/6 mice on days7 and 14 post-
tumor inoculation. We  observed  that  intratumoral  therapy incorporating mDC.Tbet (CCR7
-/-
) 
provided a level of anti-tumor protection that was indistinguishable  from  that  seen  in   
MCA205-bearing  mice  treated  with  wild-type mDC.Tbet  (Fig.  18C).This suggests that the   
therapeutic action mediated by i.t. administration of mDC.Tbet likely occurs principally in the 
TME, with minimal required involvement of secondary lymphoid tissues. 
 
Figure 18. Host crosspresenting DC and the ability of intratumorally delivered mDC.Tbet (WT) to 
traffick to tumor-draining lymph nodes are not required for the antitumor efficacy of this therapeutic 
approach 
C B A 
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MCA205 tumors were established subcutaneous in the flanks of syngenic BATF3
−/−
 (A) or CD11c-DTR (B) mice. 
On days 7 and 14 after tumor inoculation, 10
6
 mDC.Null (WT) or mDC.Tbet (WT) were injected intratumorally, 
with tumor growth monitored every 3–4 days and the tumor size reported in mm2 (mean±s.d. of five animals per 
group). In b, host CD11c
+
 DC were depleted in vivo by intraperitoneal administration of DT as described in 
Materials and methods section. In C, established subcutaneous MCA205 tumors in wild-type C57BL/6 mice were 
treated with days 7 and 4 intratumoral injections of 10
6
 mDC.Null or mDC.Tbet generated from either C57BL/6 WT 
mice or syngenic CCR7
−/−
 mice and tumor size monitored longitudinally. Data are representative of three 
independent experiments performed. *P<0.05 for mDC.Tbet (WT or CCR7
−/−
) versus mDC.Null (WT) (ANOVA) at 
the indicated time points; not significant difference (NS) in b for mDC.Tbet (WT) versus mDC.Tbet (WT)+DT or in 
c for mDC.Tbet (CCR7
−/−
) versus mDC.Tbet (WT) (ANOVA). Panel data are representative of three independent 
experiments performed. 
 
4.4.5 Intratumorally-delivered mDC.Tbet promote superior early recruitment/activation 
of Type-1 CD8
+ 
 T cells and NK cells within the therapeutic TME in association with 
enhanced  production of chemokines 
Several recent publications suggest that vast majority of DC delivered into a tumor lesion in vivo 
fail to migrate out of the tumor lesion [219, 230, 231], suggesting that their predominant 
therapeutic impact likely occurs within the TME. Although somewhat unconventional, previous 
reports suggest that the crosspriming of naïve, antigen-specific T cell responses can occur in 
extranodal tissue sites including bone marrow, skin, lungs and even tumors [228, 232-234] To 
evaluate whether early recruitment and activation of Type-1 T cell and NK cell responses were 
occurring in the MCA205 microenvironment, we established tumors s.c. in syngenic (H-2b) 
Tbet-ZsGreen reporter mice that encode ZsGreen protein driven-off a genomic Tbet/TBX21 
promoter [235]. Tumor-bearing mice were left untreated, or they were treated with i.t. delivered 
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mDC.null or mDC.Tbet generated from wild-type C57BL/6 mice. Two days later, tumors were   
harvested   and  tissue   sections   evaluated   by  fluorescence  microscopy  for Type-1-polarized 
CD4
+
  T cell, CD8
+ 
 T cell and NK (NKp46
+
) cell responses based on the conditional (Tbet-
ZsGreen) green fluorescence of these lymphoid subsets [235]. As shown in Fig. 19A/19B, within 
a 48h period of administering mDC.Tbet into tumors, a dramatic increase in Type-1 (T-bet+) NK 
cells as well as CD4+ and CD8+ T cells within the TME was observed when compared to 
MCA205 tumors in control treated mice.  Consistent with many of these recruits representing 
“naïve” cell populations, fluorescence microscopy revealed  a  preponderance of   
CD45RB
+
CD3
+
   TIL   in   mDC.Tbet   (WT)   but   not control-treated mice (Fig. 19C; appendix 
Table I), with 60% of CD45RB
+
CD3
+
  T cells coexpressing Tbet-ZsGreen
+
  (appendix Table 1).  
 
Figure 19. Early recruitment and activation of Type-1 T cells and NK cells in the TME after 
intratumoral delivery of mDC.Tbet versus mDC.Null 
A 
B 
C 
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In A, MCA205 tumors were established subcutaneous in the flanks of syngenic (H-2
b
) Tbet-ZsGreen reporter mice. 
On day 7 after tumor inoculation, 10
6
 mDC.Null (WT) or mDC.Tbet (WT) were injected intratumorally. After 2 
days, (i.e. days 9 after tumor inoculation), animals were euthanized and tumor isolated for fluorescence microscopy 
analysis of infiltrating CD4
+
 T cells, CD8
+
 T cells and NKp46
+
 NK cells as described in Materials and methods. In 
situ activated Type-1 host cells express ZsGreen protein as a consequence of transcription driven off the mTbet 
promoter. In B, quantitation of events in A images was performed using the Metamorph software and is reported as 
the mean±s.d. of 10 high-power fields per specimen. In c, tumor sections from A were analyzed by fluorescence 
confocal microscopy for the presence of ‘naïve’ T cells based on coexpression of CD45RB (blue) and CD3 [236], 
with intrinsic Tbet-ZsGreen expression indicated in green. White arrows indicate CD45RB
+
CD3
+
 T cells (red/blue 
overlay yielding a fuschia pseudocolor). Quantitation of fluorescence images was performed using Metamorph 
software and is reported in appendix Table 1. Panel data are representative of three independent experiments 
performed. 
 
Since such acute recruitment (and “priming”) of T cells and NK cells into/within the 
TME would  be  most simply explained based on chemokines elaborated from i.t.-delivered 
mDC.Tbet, we performed chemokine gene expression profiling of mDC.Tbet (WT) versus 
mDC.Null (WT). As shown in Fig. 20, mDC.Tbet intrinsically produced delevated levels of the  
chemokines  CCL1,  CCL4,  CCL6,  CCL12,  CCL17,  CXCL12  and  CXCL15  when compared 
with control DC. 
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Figure 20. Differential expression of chemokine transcripts by mDC.Tbet versus control mDC.Null 
mDC.Tbet (WT) and mDC.null (WT) were prepared as outlined in Materials and methods and allowed to incubate 
for an additional 48h after infection with recombinant adenovirus. After extracting mRNA from both cell 
populations, chemokine/chemokine receptor transcripts were then analyzed using a commercial real-time reverse 
transcription-polymerase chain reaction array as described in Materials and methods. The ratio of transcript levels 
for a given gene product among total tumor mRNA isolated from mDC.Tbet versus mDC.Null is reported. 
4.5 DISCUSSION 
The major finding of this work is that DC engineered to express high levels of the Type-1 
transactivator protein T-bet (aka TBX21) and injected into established MCA205 sarcomas 
promote therapeutic immunity via an unconventional mechanism in an unconventional location 
in tumor-bearing mice. Our data suggest that mDC.Tbet slows tumor growth via an immune-
mediated mechanism involving the activation of effector CD8+   T cells and NK cells, that 
the (acute) cross-priming of anti-tumor CD8+    T cells does not qualitatively require intrinsic 
expression of MHC class I molecules on the cell surface of injected DC, nor does it involve the 
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critical participation of host (CD8α+CD11c+  or CD103+CD11bneg) DC  populations  
classically  known  to  promote  the  robust  crosspriming  of  T  cells. Furthermore, the 
injected DC need not have the intrinsic capacity to produce IL-12 family cytokines (i.e.  IL-12,   
IL-23,  IL-35)  or  IFN-γ,  or  to  migrate  to  TuDLN  based  on responsiveness to CCR7  
ligand  chemokines. Interestingly, the injection of mDC.Tbet directly into the tumor lesion 
appears to support the rapid recruitment and activation of Type-1 (Tbet+) T cells and NK cells 
within the TME, which allows extranodal priming of protective immunity in the TME. Our 
hypothetical model of this paradigm does not preclude additional (more conventional)  cross-
priming of protective CD8+   T cells in TuDLN, however, the treatment-associated benefits of 
effector cells elicited in this manner appear modest in comparison with those promoted within 
the TME as a consequence of mDC.Tbet administration. 
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      Naive T cells (including recent thymic emigrants; RTE) are believed to circulate 
through non-lymphoid tissues as part of their normal migratory pathway, and can also be recruited 
or retained in peripheral (non-nodal) sites based on locoregional production of chemokine ligands 
for CCR7 (i.e. CCL19, CCL21), CCR9 (i.e. CCL25) and CXCR4 (CXCL12/SDF-1α;) [237-239]. 
Under such (unconventional) conditions, extranodal priming of naïve T cells has been reported 
to occur in a range of tissues including the bone marrow, liver, lungs, skin and even tumors 
[228, 232, 234, 240-242]. Notably, the (cross)priming of protective T cells can be leveraged by 
the selective production of recruiting chemokines, as a consequence of gene therapies applied to 
the TME [242, 250-252] [87, 233, 243]. NK cells, which can mediate tumoricidal activity as well 
as the “licensing” of DC for improved T cell crosspriming capacity [253, 278] [244, 245], may 
also be recruited into extranodal tissue sites based on DC-produced chemokines such  as
 CCL1/I-309, CCL2/MCP-1, CCL4/MIP-1, CCL5/RANTES, CCL7/TARC, 
CCL22/MDC, CXCL8/IL-8 or CXCL10/IP-10 [246-248]. Also of significant interest, a recent 
report by Messina et  al. [247] suggests that a 12 chemokine (i.e. CCL2-CCL5, CCL8, 
CCL18-CCL21, CXCL9-CXCL11 and CXCL13) gene signature may be associated with the 
presence of lymph node-like stuctures within the TME of advanced-stage melanomas and be 
predictive of patient responsivenss to immunotherapy and overall survival. In this regard, our 
transcriptional profiling of murine DC.Tbet suggest the differential ability of DC.Tbet versus 
control DC to produce the NK (CCL1, CCL4, CCL6, CXCL12) and naïve T cell (CCL4, CCL17, 
CXCL12) recruiting chemokines Fig. 6; refs. [238]). in support of extranodal induction of 
protective immunity in the TME. Of these, CCL1 (which along with CCL17 promotes extended 
cognate interaction of naïve T cells with DC and consequent Type-1 T effector cell polarization) 
[68] and CCL4 were also overexpressed at the transcript level by human DC.Tbet versus 
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control human DC (appendix Table 2). Future experiments employing neutralizing antibodies 
or shRNA knock-down of these chemokines in injected DC.Tbet may allow us to determine 
the intrinsic importance of one or more of these soluble recruiting molecules in the anti-
tumor efficacy of our DC-based gene therapy and to discern whether this treatment approach 
supports the establishment of lymph node-like structures in the TME over time in cases of 
stabilized disease. 
Once recruited into the TME as a consequence of  i.t.-delivered mDC.Tbet, optimal 
crosspriming of anti-tumor CD8+  T cells is likely mediated predominantly by the injected 
mDC.Tbet that have acquired, processed and presented tumor-associated antigens in the MHC  
class I complexes in situ, based on results obtained in our studies employing therapeutic  
mDC.Tbet generated from β2M-/- mice. However, even though mDC.Tbet (β2M-/-) support the 
induction of some degree of protective CD8+ T cell-mediated immunity, the resultant anti-tumor 
protection associated with this immunity appears to be of a lower quality/durability than that  
developed in therapies using mDC.Tbet (WT). Such lower therapeutic efficiency/efficacy 
linked to administration of mDC.Tbet (β2M-/-) could be the result of one or more limitations, 
including but not limited to; i.) the provision of suboptimal activation signals by mDC.Tbet 
(β2M-/-) to cognate T cell responders based on the limited crosspresenting ability of these MHC 
class I-deficient APC; ii.) the modest ability of these APC to crossprime/boost protective CD8+ T 
cells in secondary lymphoid organs; and/or iii.) premature demise or NK-mediated eradication of 
these MHC class-deficient APCs in vivo thereby limiting the functional duration of adaptive 
immune stimulation [249]. With regard to the first point, it is conceivable that despite a genetic 
deficiency in β2M expression, that mDC.Tbet (β2M-/-) may acquire a limited capacity to activate 
tumor-specific CD8+ T cells in the TME via the pirating of tumor membrane components or the 
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uptake of tumor-derived exosomes, both of which contain MHC class I/peptide complexes 
[ 250] .  Alternatively or additionally, soluble β2M (found in microgram/ml quantities in 
serum) may be taken up along with tumor antigens by mDC.Tbet (β2M-/-), allowing for the 
stabilization of sufficient MHC I/tumor peptide complexes [251] on the injected DC cell surface 
to allow for at least a limited degree of specific T cell induction in the TME. It is also 
conceivable that mDC.Tbet + NK cells condition the TME to allow for the priming/activation of 
CD8+ T cells by CD11cneg tumor-associated macrophages or even tumor cells themselves, 
although these would likely be considered as inefficient APC for this purpose [178]. 
That extranodal (cross)priming of T cell responses in peripheral tissues versus secondary 
lymphoid organs may yield a responding T cell repertoire that differs in overall magnitude or 
quality has been previously suggested in infectious disease models in CCR7-/- mice [228]. When 
challenged with aerosolized live mycobacteria, CCR7-/- animals crossprime specific T cells in the 
lungs rather than the mediastinal lymph nodes [228].  The resulting immunity protects against 
only low doses of bacterial rechallenge, in contrast to wild-type mice vaccinated in a similar 
manner, in which case the animals withstand far greater doses of bacterial challenge [228]. This 
paradigm could underlie the inability of anti-tumor T cells crossprimed by mDC.Tbet (β2M-/-) to 
regulate the growth of MCA205 tumors after they reach a certain size (i.e. tumor load), resulting 
in lethal, progressive disease. Our data also suggest that the inherent quality (and anti-tumor 
efficacy) of anti-tumor CD8+ T cells is dominantly imprinted at the time of first i.t. delivery of 
mDC.Tbet, since a booster injection of mDC.Tbet (WT) did not dramatically reinforce the anti-
tumor protection initiated by mDC.Tbet (β2M-/-). This interpretation is further supported by 
our findings that within 2 days of i.t. delivery of mDC.Tbet more than ½ of the enriched 
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population of CD45RB+CD3+ TIL already expresses early evidence of Type-1 polarization (Fig. 
19C, appendix Table 1).  
The theoretical locoregional impact of “booster” mDC.Tbet  delivered  i.t.  on  day  14 
post-tumor inoculation on protective CD8+ T cells resulting from the initial administration of 
mDC.Tbet  into  the  TME  may  be  extrapolated  from  previous  studies  in  which 
genetically-modified  DC  were  injected  i.t.  in  concert  with  the  adoptive  transfer  of pre-
activated  tumor  antigen-specific  CD8+  T cells  [179, 252, 253]. Thus DC engineered to 
produce IFN-γ enhanced recruitment of i.v. administered Type-1 anti-tumor CD8+ T cells in a 
CXCL10/IP-10 chemokine-dependent manner [178]. Also in this light, several recent reports  
[179, 252] are intriguing since i.t. delivery of DC loaded with tumor antigens (versus unloaded 
DC)  was observed to maximally enhance the accumulation and anti-tumor efficacy of 
adoptively-transferred or vaccine-induced tumor antigen-specific CD8+  T cells. This suggests 
that the crosspresentation of cognate antigen by injected mDC.Tbet (rather than or in addition to 
tumor cells themselves) to CD8+ T cells in the TME may be critical for optimal and sustained 
anti-tumor T effector cell function in vivo. Booster i.t.-delivered mDC.Tbet would also  be 
expected to intrinsically produce or  promote the IFN-γ-dependent  (from  Type-1  T  cells  and  
NK  cells)  elaboration  of  CXCR3  ligand chemokines  [ 178 ,  219] ,  thereby  reinforcing  the  
recruitment  and/or  sequestration  of protective anti-tumor CD8+ T cells into/within the TME 
and extending the window of therapeutic tumor management. 
When taken together, our data support the ability of i.t. delivered mDC.Tbet (WT) to 
recruit, prime and sustain superior Type-1 anti-tumor immunity within the TME. 
Intratumoral delivery of hDC.Tbet would be predicted to have translational merit in the 
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context of vaccines and as a co-therapy with adoptive cellular therapy in patients with accessible 
(i.e. injectable) forms of solid cancer. 
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5.0  SUMMARY AND INTERPRETATION 
5.1 PROPOSED MODEL FOR THE ANTI-TUMOR ACTION OF DC.TBET 
Based on the notion that T-bet expression in DC subsets controls the Type 1 priming function of 
these cells [4, 153],  we hypothesized that the reinforcement of T-bet expression in DCs using 
rAd.T-bet viral transfection would yield robust DC1-type APCs that were competent to 
(re)polarize Type-1 anti-tumor T cell responses in vitro and in vivo. We first demonstrated that 
gene-modified human dendritic cells that highly express T-bet protein (DC.Tbet) strongly 
promoteD Type-1 T cell polarization from naïve cell responders while concomitantly 
suppressing Th2 and Treg development [175]. ref. Interestingly, the Type-1 polarizing function 
of human DC.Tbet seems to be largely independent of IL-12 family cytokines as these DCs were 
suppressed in their production of IL-12p70, IL-23, and IL-27, as well as all other cytokines 
evaluated; and neutralizing Abs against IL-12p70, IL-23p19, IL-12Rβ2, and IL-27R all failed to 
attenuate DC.Tbet-mediated induction of Type-1 responses from naive T cells [175]. Similar 
results were observed in our analyses of murine DC.Tbet which displayed potent Type-1 T cell 
polarizing function that was not affected by the provision of IL-12 neutralizing antibody.  
Murine DC.Tbet also mediated potent anti-tumor activity when injected intratumorally into 
MCA205 (H-2
b
) sarcoma tumor bearing mice (C57BL/6 mice), based on improved (1) cross-
priming of systemic anti-tumor Type-1 T cell responses, (2) frequencies of Type-1 TILs and 
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CD11c
+
 DCs in the TME, (3) normalization of the TME (based on reductions in MDSC 
frequencies and vascular complexity), and (4) frequencies of apoptotic (TUNEL
+
) tumor cells in 
the TME.   
Using the MCA205 (H-2
b
) sarcoma model and transgenic mice as sources of injected 
DC.Tbet into tumor-bearing mice, we characterized a series of molecular and cellular events that 
are likely responsible for the anti-tumor function of DC.Tbet. Consistent with the IL-12 
independent Type1-polarizing function observed in DC.Tbet in vitro, the protective effects of 
i.t.-delivered DC.Tbet were demonstrated to be independent of the intrinsic production of IL-12 
family cytokines (IL-12, IL-23, and IL-27) and IFN-γ. Since IL-12 family cytokines are 
important anti-tumor mediators, these data indicate that DC.Tbet employ a unconventional 
therapeutic mechanism(s) that is less dependent on the cytokines secreted by DCs. Interestingly, 
depletion of either NK cell or CD8
+
 T cell populations completely ablated anti-tumor benefit 
afforded by DC.Tbet suggesting that both NK cells and CD8
+
 T cells were required for the anti-
tumor immunity driven by DC.Tbet. NK cells were needed throughout the whole treatment as 
late depletion of NK cells (beginning on day 13 post tumor inoculation) still affected the 
therapeutic benefit of DC.Tbet. In this regard, DC.Tbet might work through NK cells to 
optimally activate tumoricidal CD8
+
 T cells, which would explain the nearly complete ablation 
of therapeutic effect of DC.Tbet upon NK depletion. Indeed, it has been reported that the cross-
talk between DCs and NK cells in the TME or SLO facilitated the development of anti-tumor 
immune responses [254, 255]. NK-DC crosstalk promotes DC1 (Type-1 DC) development and 
the corollary induction of Th1 and CTL responses [256, 257]. On another hand, DC-based 
vaccination promotes NK cell activation which may also be required for subsequent inhibition of 
tumor metastasis [258].   DCs can activate NK cells through cytokines such as IL-12, IL-15 and 
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Type-1 IFN which are known to enhance NK cell production of IFN-γ, proliferation and 
cytolytic activity [256]. Cell-cell interactions between DC and NK cells might also activate NK 
cells through surface receptors on DCs (such as NKG2D) [259, 260]. In our study, the 
mechanisms by which DC activate NK cells may involve the direct transfer of T-bet protein from 
DC.Tbet to NK cells, as indicated by the transfer of T-bet protein from DC.Tbet (but not control 
DC) to T cells in vitro (Appendix Fig. 8), and T-bet as an important transcription factor controls 
the maturation and effector function of not only T cells, but also NK cells [61].   
MHC class I expression on DC.Tbet is required for their optimal anti-tumor function as 
β2m-/-DC.Tbet used as either the first or the second treatment modality failed to induce efficient 
anti-tumor immunity when compared to tumor-bearing mice treated i.t. with wild-type (WT) 
DC.Tbet. It appears that although MHC class I expression on injected DC.Tbet may not be 
required for the initial induction of anti-tumor immunity, but that it is likely needed for the 
sustained function and therapeutic action of T effector cells in treated mice on or after day 16 of 
treatment. Interestingly, despite the expected requirement of MHC class I for direct cross-
presentation of antigen to T cells by injected DC, β2m-/- DC.Tbet were still able to induce WT-
level tumor-specific CD8
+ 
T cell responses in the first 10 days post–treatment. Several 
mechanisms might explain this result: 1) β2m-/- DC.Tbet might pick up soluble β2m from the 
TME or they might acquire intact MHC-peptide complexes from tumor cells upon cell-cell 
contact; 2) β2m-/- DCTbet may recondition the TME so that tumor cells/other innate immune 
cells such as macrophages could serve as APCs to prime tumor-specific CTL responses; 3). β2m-
/- 
DC.Tbet may activate NK cells to facilitate the T cell priming in the TME.  
CCR7
-/-
 DC.Tbet that are incapable of migrating to lymph node still provided a similar 
level of anti-tumor protection as WT DC.Tbet, indicating that the therapeutic action mediated by 
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DC.Tbet likely occurred principally in the TME, with minimal required involvement of SLO. 
As early as day 2 post-treatment, a dramatic increase in Type-1 (T-bet+) NK cells as well as 
CD4+ and CD8+ T cells were observed within the TME when compared to MCA205 tumors in 
control treated mice; naïve T cells (CD3
+
CD45RB
+
) were also observed in the TME within 
48hrs post treatment with around 60% of these TIL expressing T-bet (T-bet-ZsGreen
+
). A 
corroborative staining with CD44 (CD3
+
CD45RB
+ 
CD44
- 
or CD3
+
CD62L
+ 
CD44
-
) should be 
used in future experiments to better discern the naïve T cell phenotype. It is likely that DC.Tbet 
support the extranodal priming of naïve T cells in the TME, possibly in the tertiary lymphoid 
organs (TLOs) induced by intratumorally injected DC.Tbet. The formation of TLOs has been 
reported in the TME of many tumor types (lung cancer, melanoma, colon cancer etc), and the 
presence of TLOs in TME usually predicted better clinical outcome [247, 259, 260]. 
Immunohistochemichal staining of tumor sections isolated 5 days post DC.Tbet treatment 
revealed lymphoid-like structures featuring condensed T cells areas in the TME. Further staining 
for B cells (B220, CD19) and HEV markers (MECA-79, HECA-452, G72, and G152) are needed 
to define these structures.  
Normally, CCR7 expression is required for the migration of DC into draining SLO [261, 
262]. Although DC.Tbet lacking CCR7 (generated from CCR7
-/-
 mice) provided wild type 
therapeutic protection, it was unclear whether a very small (but highly functional) portion of 
injected DC.Tbet trafficked into LN leading to the priming of anti-tumor immune responses in 
the TDLN. Thus, in future studies, DC.Tbet traffick in vivo should be analyzed in depth using 
intravital microscopy tracing of fluorescently-labeled DC.Tbet or immunofluorescence staining 
of DC.Tbet (labeled or origins from T-betZsGreen
+
 mice) in LN at various longitudinal time 
points.  Mice lacking functional SLO such as Lymph Toxin α-deficient (LTα-/-) mice would 
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serve as a useful tool to study if SLOs including TDLN is at all needed in DC.Tbet mediated 
anti-tumor Type-1 immunity development.  
It will also be important to identify the “pioneer” cell types that are recruited into the 
TME immediately post treatment, as these cells might play crucial roles in the establishment of 
TLOs in the TME. It is possible that extranodal priming of anti-tumor T cell responses is not just 
restricted to DC.Tbet based therapy but is a common mechanism associated with other DC-based 
vaccine strategies (with variation based on the magnitude of TLO formation elicited). Analysis 
of extranodal T cell priming and the formation of TLOs in the TME of mice treated with other 
DC vaccines will be necessary to establish the generalizable impact of extranodal T cell priming 
on the anti-tumor efficacy of DC-based cancer immunotherapies. 
Based on these data, I would propose a hypothetical model for the anti-tumor action of 
DC.Tbet (Figure 21). In this model, DC.Tbet upon i.t. delivery into TME, promotes rapid 
recruitment of naïve T cells and NK cells through:  1) chemokines secreted by DC.Tbet 2). 
chemokines produced by other immune cells (Macrophage, NK cells etc) or tumor cells 
reconditioned by DC.Tbet. Once arrive in the TME, these immune effector cells further enhance 
chemokines production in the TME through interacting with the tumor cells or other immune 
components in the TME, which continue to recondition the TME and lead to the recruitment of 
subsequent immune cells. It is likely that CD4
+
 T cells are among the early recruited cell 
populations as the mature CD4
+
 T cells interact with DCs to promote the formation of TLOs. 
The majority of anti-tumor T cell (cross)priming happens extranodally in the TME, with 
DC.Tbet strongly promoting the development of Th1 and tumor killing CD8
+
 T cells; these 
primed CD8
+
 T cells remain in the TME where they are sustained by secondary i.t. injection of 
mDC.Tbet, although some peripheral (tumor-draining lymph nodes, spleen) expansion of the 
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antitumor CD8
+
 T-cell may also be therapeutically potentiated over time. On another hand, 
DC.Tbet reduce the number of immunosuppressive cells MDSC and Tregs, and promote the 
normalization of tumor vasculature which facilitate the anti-tumor immunity in the TME.  The 
early tumor regression observed in 7-10 days post the first DC treatment are not heavily 
dependent on the direct cross-priming of CD8
+
 T cells by DC.Tbet, rather it may result from 
multiple alternative mechanisms: 1) NK cells are recruited and activated by DC.Tbet through 
DC-NK crosstalk which enhances the NK cytolytic activity and promotes the helper activity of 
NK cells; 2) DC.Tbet recondition the TME to recruit immune cells and to foster the non-DC 
mediated tumor antigen presentation to anti-tumor CD8
+
 TIL. 
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Figure 21. A hypothetical model for extranodal priming of therapeutic immunity in the TME after 
intratumoral delivery of mDC.Tbet 
In this model, delivery of mDC.Tbet leads to the acute recruitment of NK cells and naive CD8
+
 T cells, based on 
injected DC production of chemokines. Such recruitment into the TME fosters the crosspriming and polarization of 
antitumor CD8
+
 T cells in a manner independent of IL-12 family member cytokine or IFN-γ production by the 
injected mDC.Tbet cells. Optimal induction of protective immunity requires MHC class I expression by the injected 
DC-based on our observations for the inferior quality/durability of protective CD8
+
 T cells developed in therapies 
using intratumorally delivered DC.Tbet (β2M−/−). Host DC populations do not have dominant roles in the 
therapeutic benefits associated with intratumoral delivery.  
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5.1 SUMMARY OF STUDIES RELATED TO THE MOLECULAR MECHANISMS 
UNDERLYING THE TYPE-1 POLARIZING FUNCTION OF DC.TBET 
Gene array analysis were performed on human DC.Tbet vs. control DCs (DC.ѱ5) in order to 
study differentially expressed gene sets that might contribute to the superior Type-1 polarizing 
action mediated by DC.Tbet. In these studies, DC.Tbet and DC.ψ5 were generated from 5 
unrelated healthy donors, and treated with or without IFN-γ and LPS in the medium for 24 hrs. 
All 20 samples were then analyzed by gene expression profiling using an oligonucleotide 
microarray with more than 44,000 probes (Agilent) (appendix Fig. 7).    1563 genes were 
differentially expressed between these 4 groups of DCs (F test, p less than 0.05). Hierarchical 
clustering analysis of these differentially expressed genes suggest that differences between IFN-γ 
and LPS treated DC.Tbet and treated DC.ѱ5 are greater than those between untreated DC.T-bet 
and untreated DC.ψ5 (appendix Fig. 7A, B), suggesting that upon activation DC.Tbet further 
changes the expression of many genes that might contribute to the immunostimulatory function 
of DCs. Comparison of untreated DC.Tbet with untreated DC.ѱ5 revealed 343 up-regulated 
genes and 560 down-regulated genes in DC.Tbet. Genes up-regulated in untreated DC.Tbet were 
most likely to belong to the following functional groups: Cellular Movement, Inflammatory 
Response, Organismal Functions, Hematopoiesis, and Immune Cell Trafficking. Genes down-
regulated in untreated DC.Tbet were most likely to belong to the following functional groups: 
Cardiovascular Disease, Genetic Disorder, Skeletal and Muscular Disorders, Cellular Movement 
and Immunological Disease. Genes up-regulated in LPS and IFN-γ treated DC.Tbet were most 
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likely to belong to the following functional groups: Inflammatory Response, Organismal Injury 
and Abnormalities, Respiratory Disease, Cancer and Infection Mechanism (data not shown). 
Genes down-regulated in treated DC.Tbet were most likely to belong to the following functional 
groups: Cellular Movement, Hematological System Development and Function, Immune Cell 
Trafficking, Inflammatory Response and Inflammatory Disease (data not shown). Up-regulate 
genes in treated DC.Tbet seemed to associate with immune functions, including inflammatory 
response, cancer and infection mechanism, cellular movement, hematological system 
development and function, and immune cell trafficking. 
Pathway analysis suggest that genes in the hepatic fibrosis/hepatic stellate cell activation 
and LXR/RXR activation pathways were downregulated in both treated and untreated DC.Tbet. 
The LXR/RXR related pathways are interesting since LXR pathway activation was shown to 
interfere with DC maturation and to negatively regulate T cell simulation driven by DCs [263]. 
 Several genes that are highly up-regulated (2 fold or more) in microarray were evaluated 
by RT-PCR (to confirm the expression; data not shown) and are studied for their function. 
RRAD is a Ras-related GTPase that may be involved in cytoskeleton reorganization (important 
for cosimulatory activity and signal transduction) [264] and insulin resistance in diabetes [265]; 
it may also act as a functional tumor suppressor [266]. Another two Ras-related GTPase, Rac1 
and Rac2 were reported to regulate the T cell priming function in DCs [267].  To better 
understand the role of RRAD in DC.Tbet functionality, a recombinant adenovirus carrying 
RRAD (rAd.RRAD) cDNA was generated by the Vector Core Facility of the UPCI and used to 
transduce DCs in gain-of-function studies. To date, the transduction of DCs with rAd.RRAD was 
not successful in generating DC expressing high levels of RRAD protein. This might be due to 
poor adenovirus vector quality or to unknown regulatory mechanisms in DCs that restricted 
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ectopic over-expression of RRAD under a viral promoter (this is less likely as successful 
upregulation of RRAD in cultured fat and muscle cells has been previously achieved) [265]. 
Several transmembrane proteins of the tetraspanin superfamily were be upregulated in 
expression by DC.Tbet when compared with DC.5 (Tetraspanin12, Tetraspanin2 and 
Tetraspanin17). Tetraspanins regulate cell migration and fusion [268], signaling transduction, 
immune response and protein trafficking [269, 270].  Tetraspanins are capable of associating 
with each other and partner/signaling proteins and forming lateral organization of membrane 
proteins – Tetraspanin Enriched Domains (TEM) [271]. TEM usually contains integrins, 
adhesion molecules [ICAM-1, VCAM-1 etc], signaling molecules such as GPCR [271], and 
MHC molecules, CD4, CD8 and CD19 in immune cells [272].  TEM on DCs are believed to 
preorganize MHC-peptide complexes before encountering T cells to facilitate the  activation of 
cognate T cells, and the adhesion and proliferative function of leukocytes [273]. Tetraspanins are 
also preferentially found in exosomes/microvesicles and might contribute to the 
immunostimulatory function of these cell-free structures [274]. To assess the impact of 
transgenic Tsp12, I generated rAd.Tsp12 vectors and transduced DC. DC.Tsp12 displayed only 
weak T cell priming capacity in vitro when pulsed with SEB and cocultured with naïve T cells 
(data not shown). These data suggest that high levels of Tsp12 may be a biomarker asociated 
with the superior Type-1 polarizing potential of DC.Tbet, but that this molecule is not intimately 
involved in this immunologic process. Another interesting factor found to be highly-
overexpressed in treated DC.Tbet was IL-36γ, a newly identified IL-1 family cytokine that 
promoted Th1 cell responses from naïve T cell precursors in vitro [275]. The study of DC.IL36 
and the impact of neutralizing IL-36 in DC.Tbet via the use of siRNA knock-down or the 
application of neutralizing antibody is an active area of future work by our laboratory.  
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Among the down-regulated genes observed in DC.Tbet vs. control DC were CCL2 and 
CCL7. These chemokines are of special interest as they may be associated with the inhibition of 
accumulation of MDSC in tumors treated with DC.Tbet [276]. In addition, MARCH-I 
(Membrane-associated RING-CH-1) is an ubiquitin ligase that regulates the ubiquitination of 
MHC class II and B-7 molecules on DC surface [277, 278]. The down-regulation of MARCH-I 
in mature/activated DCs lead to the upregulation and stabilization of MHC class II and may 
enhance the immunostimulatory function of DCs [279, 280]. The over-expression and down-
regulation of MARCH-I in DCs by adenoviral-mediated gene transduction and/or RNA 
interference manipulation, respectively, could be used to study the role of differential MARCH-I 
expression in DC.Tbet-mediated function and anti-tumor efficacy.  
Several proteins such as IL-1β and Wnt that participate in non-classical secretion 
(microvesicle/exosome mediated secretion) pathways [281, 282] were also determined to be 
upregulated in DC.Tbet when compared to control DCs. Microvesicles (MVs) are membrane 
fragments secreted from the endosomal membrane compartment with a size range from 30nm-
1000nm (exosome 30-100nm, MVs 100-1000nm) [283]. MVs may carry and transfer mRNA and 
proteins between cells, and these structures are capable of directly stimulating immune cells or to 
serve as immune suppressors depending on their cellular source [283-285]. I believe that 
DC.Tbet upregulate their secretion of MV/exosomes leading to: 1) directly activation of T 
effector cells; 2) the transfer of T-bet protein/mRNA from DC.Tbet to nearby T cells and other 
immune cells. To test this hypothesis, I harvested microvesicles from the day 2-cultured 
supernatants of DC.Tbet and DC.ѱ5 by sequential supercentrifuge and then analyzed their 
protein content by western blot (appendix Fig. 8B). DC.Tbet seem to produce more MVs as a 
bigger pellet size was consistently associated with the centrifuged product isolated from 
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DC.Tbet’s culture supernatant (from 3 different experiments). Transmission electron microscopy 
revealed a heterogeneous composition of MVs with vesicles’ size spanning from 60-200 nm in 
diameter. Western-blotting analysis of these vesicles suggested these MVs contained high levels 
of MHC molecules and Tsp12 (data not shown). Interestingly, MVs derived from DC.Tbet, but 
not control DC.5, also contained abundant concentrations of T-bet protein. When directly 
adding these MVs into naïve T cell cultures, DC.Tbet-derived MVs displayed stronger Type-1 T 
cell priming capability when compared to MVs derived from control DCs (appendix Fig. 8C).  
Overall, these data suggest that DC.Tbet-derived MVs contain T-bet protein, and these MVs are 
capable of promoting Type-1 T cell responses over short distances in vitro, which may partially 
explain the superior Type-1 polarizing function of DC.Tbet.  
 The fact that MVs derived from DC.Tbet contains T-bet protein indicates the possibility 
of T-bet protein/mRNA transferring from DC.Tbet to T cells or other cells in the proximal 
microenvironment. To test this hypothesis, I co-cultured SEB -pulsed DC.Tbet with T cells 
derived from T-bet
-/- 
splenocytes, after 2-4 hrs T-bet content in these T cells was analyzed by 
flow cytometry. As shown in Appendix Fig. 8D, about 0.5% T-bet positive events were observed 
amongst intrinsically T-bet
-/- 
T cells, suggesting that T-bet protein were actively transferred from 
DC.Tbet to T-bet
-/- 
T cells. Repeating this experiment again using SIINFEKL (OVA)-pulsed DC 
and OT-I (anti-SIINFEKL) TCR transgenic T cells demonstrated that Ag-specific contact 
between DC.Tbet and T cells led to the enhanced transfer of T-bet from DC.Tbet to T cells. In 
future experiments, MVs from DC.Tbet will be evaluated for their potential in mediating T-bet 
protein transfer to T cells in the therapeutic setting. 
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Appendix Figure 1. DC.Tbets promote Type-1 (IFN-γ) responses from CD45RO−CD56− and 
CD45RO
−
CD4
+
T cells in vitro.  
Cultures were established as outlined in Fig. 2A using bulk CD45RO
−
 cells or CD45RO
−
 cells depleted of 
contaminant CD56
+
 cells using MACS (A) as responders. Culture supernatants were evaluated for IFN-γ production 
after 72 h of coculture using a specific ELISA (B). Alternatively, MACS-isolated CD45RO
−
CD4
+
 and 
CD45RA
−
CD4
+
 T cells (C) were used as responders, with day 3 culture supernatants evaluated for IFN-γ levels (D). 
∗, p < 0.05 for DC.Tbets vs DC.nulls or DC.ψ5. All data are representative of two independent assays performed.  
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Appendix Figure 2. DC.Tbet selectively prime Type-1 (IFN-γ) responses from 
CD45RO
−
CCR7
+
CD62L
+
 naive T cells  in vitro.  
CD45RO
−
 or CD45RA
−
 cells were subsequently subdivided into CCR7
+
 and CCR7
−
 subpopulations using specific 
MACS beads and evaluated for their phenotypes by flow cytometry using mAbs against CCR7 and CD62L (A). 
These four cell populations were then used as responders against autologous, SEB-pulsed DC.Tbet or control DC as 
described in Fig. 2A. Day 3 coculture supernatants were evaluated for IFN-γ content by ELISA (B). ∗, p < 0.05 for 
DC.Tbet vs DC.null or DC.ψ5 . All data are representative of two independent assays performed. TE, Effector T cell; 
TCM, central memory T cell; TEM, effector memory T cell.  
 
 117 
 
Appendix Figure 3. Phenotypes of DC.Tbet vs. control DC.  
DC.Tbet and control DC were generated as outlined in Materials and Methods and phenotyped by flow cytometry. 
With the exception of the CD11c cohort itself, in all other populations, cells were initially gated on CD11c+ events 
and then assessed for expression of the indicated markers using specific antibodies/ Data are representative of 6 
independent experiments performed, each using a different donor. 
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Appendix Figure 4. The ability of DC.Tbet to promote superior Type-1 T cell responses in vitro is not 
inhibited by blockade of DC-expressed CD70 or NOTCH ligands.  
A. DC.Tbet were initially analyzed for cell surface expression of CD70 or the NOTCH ligands Jagged-1 (Jag-1) and 
Delta-Like 4 (DLL4) by flow cytometry. B. Naïve bulk T cells were then stimulated with SEB-pulsed DC.Tbet or 
control DC in the absence or presence of 10 µg/ml of the blocking anti-CD70 mAb or NOTCH-Fc fusion protein as 
indicated. After 3 days, culture supernatants were analyzed for levels of IFN-γ by ELISA 
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Appendix Figure 5. Intratumoral delivery of DC.Tbet enhances CD4
+
 and CD8
+
 T cell expansion and 
the development of tumor-reactive Tc1 effector cells in the tumor draining lymph node.  
Established day 7 CMS4 tumors were injected with 1X10
6
 DC.mTbet or control DC.ψ5 with an identical re-
treatment one week later. On day 21, tumor draining lymph nodes were harvested and total numbers of CD4
+
 (A) 
and CD8
+
 (B) T cells were determined by FCM. In C, MACs-purified CD8+ T cells from tumor draining lymph 
nodes were co-cultured with irradiated CMS4 tumor cells for 5 days and washed then restimulated with CMS4 
tumor cells or unrelated MethA (H-2d) sarcoma cells for 48 h. Supernatants from these restimulation cultures were 
then analyzed for mIFN-γ content by specific ELISA. Data are representative of those obtained in 3 independent 
experiments. Results were shown as reported as mean ± SD. ∗p < 0.05 for DCm.Tbets vs. DC.ψ5.  
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Appendix Figure 6. DC.mTbet exhibit enhanced persistence in the CMS4 TME and promote 
increased tumor infiltration by host CD11c
+
 DC. 
A. Established day 7 CMS4 tumors were injected with DC.mTbet or control DCs that had been pre-labeled with 
CFSE. Three days after the injection, tumor lesions were harvested, sectioned and stained with anti-CD11c PE mAb 
(BD-Biosciences). Tumor sections were also counterstained with Hoechst to detect nuclei before analysis by 
fluorescence microscopy. After analysis of 10 high-power fields (HPF), the mean+/- SD was calculated for total 
CD11c
+
 cells B, CD11c-PE
+
 only cells C,  and CD11c-CFSE
+
 cells D. Results were shown as reported as mean ± 
SD. ∗p < 0.05 ∗∗p for DC.mTbet vs. DC.ψ5  injected tumors. 
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Appendix Figure 7. Gene array analysis of DC.Tbet vs. control DCs. 
DC.Tbet and control DCs (DC.ψ5) were generated from PBMCs derived from 5 healthy donors, treated with or 
without LPS and IFN-γ for 24hrs. Total RNA from these cells were extracted from each cell line using the 
miRNeasy mini kit (Qiagen, Westburg, Leusden, NL). Gene expression experiments were performed on 4 × 44 K 
Whole Human Genome Microarray (Agilent technologies). Results were analyzed using BRBArrayTools developed 
by the Biometric Research Branch, National Cancer Institute and Cluster and TreeView software. A, Hierarchical 
Clustering Analysis of 1563 Differentially Expressed Genes among all 20 DC samples (F-test, p≤0.05); B. 
 122 
Hierarchical clustering analysis of 1485 genes differentially expressed among IFN-γ and LPS treated DC.Tbet, IFN-
γ and LPS treated DC.ψ5 and untreated DC.Tbet (F-test, p≤0.05) C. Highly up- or down-regulated genes in DC.Tbet 
(5 folds or more compared to control DCs). 
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Appendix Figure 8. Microvesicles derived from DC.Tbet contain T-bet protein and induce higher 
level of IFN-γ from naïve allo-T cells compare to DC.ψ5. 
Microvesicles secreted from DC.Tbet or DC.ψ5 were collected by sequential high speed centrifugations. The 
phenotype of these MVs were analyzed by electron microscopy (A), and the protein content were analyzed by 
western blotting (B). These vesicles were evaluated for their T cell priming efficacy in a coculture system with MVs 
and naïve T cells (CD45RA
+
) (C). In (D) SEB pulsed DC.Tbet were cocultured with T-bet
-/-   
T cells for 2-4 hrs, 
after which CD3, CD4 and T-bet were stained by immunofluorescence staining and analyzed by flow cytometry. 
Events shown in D were gated on CD3
+
 T cells. ∗, p < 0.05 for DC.Tbet vs DC.ψ5 [t-test]. 
 
 
 
D 
* 
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Appendix Table 1. MCA205 tumors in mice treated with i.t. delivered mDC.Tbet contain abundant levels 
of CD45RB
+
 CD3
+
 TIL.  
Cell phenotype 
mDC.Tbet-treated 
number of events per HPF 
mDC.Null-treated 
number of events per HPF 
CD3+ 64.3±9.8* 6.0±1.6 
CD45RB+CD3+ 40.0±5.4* 2.7±0.9 
CD45RBnegCD3+ 24.3±10.1* 3.3±0.5 
CD45RB+CD3+ZsGreen+ 25.0±6.4* 2.0±0.8 
CD45RB+CD3+ZsGreenneg 15.0±3.4* 0.6±0.5 
 
 
Fluorescence confocal microscopy images obtained in Fig. 19C were analyzed using Metamorph software as 
described in Materials and Methods, with data as the mean ± SD of 10 HPF/specimen. ∗p < 0.05 for mDC.Tbet 
(WT) versus mDC.Null (WT) [t-test]. Data are representative of those obtained in 3 independent experiments 
performed. 
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Appendix Table 2. Chemokine transcripts in hDC.Tbet versus hDC.Null (> 1.5 fold). 
Chemokine 
Analyzed 
Fold Change 
(hDC.Tbet/hDC.Null) 
p-value 
CCL1 4.814 0.009 
CCL27 1.677 0.012 
CXCL16 1.625 0.015 
CXCL11 1.581 0.028 
CCL4 1.518 0.031 
CXCL2 -2.315 0.025 
CCL2 -4.500 0.005 
CXCL1 -8.920 0.001 
 
Resting human DC were generated from the peripheral blood of 5 normal donors, with DC (both > 98% 
CD11c
+
CD14
neg
) then infected with empty adenovirus (hDC.Null) or hDC.Tbet for 48h. Message RNA was then 
extracted and gene profiling were performed as described in Appendix Fig. 7. Results are reported as mean fold 
differences.    
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